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Abstract 
Crohn’s Disease (CD) is a lifelong inflammatory disorder of the gastrointestinal tract.  It 
may manifest anywhere along the gut including anatomically remote sections of the small 
bowel.  The principal motivation behind the work described here is to meet the clinical 
need for improved means of diagnosis and management of inflammatory disorders of the 
bowel, such as CD.  Potentially, improvements can be met by augmenting capsule 
endoscopes with microultrasound.  Microultrasound (US) frequencies are > 20 MHz and 
have the potential to provide highly detailed transmural images of the bowel wall.  This 
would provide capsule endoscopes with a means of detecting and displaying subsurface 
disease and, provide clinicians with the means of treating the disease to achieve complete 
or histological remission. 
Investigating the feasibility of ultrasound capsule endoscopy (USCE) utilised explanted 
human tissue, in vivo pig trials and mouse experiments.  Human tissue experiments were 
aimed at identifying a suitable US frequency for USCE and examining the relationship 
between acoustic and histologic bowel layers.  Pig experiments aimed to demonstrate the 
technological feasibility of USCE.  The primary endpoint was to determine if sufficient 
coupling occurred between capsule ultrasound transducer(s) and the mucosa to generate 
a transmural US bowel image.  Mouse experiments were aimed at determining whether 
US could directly detect inflammation via the infiltration and accumulation of white 
blood cells.  This also included what was the lowest grade of inflammation detectable. 
Chapter 4 describes the results of scanning explanted human colon with different 
microultrasound frequencies. The purpose of this pilot study was twofold. One aim was 
to tentatively identify a suitable frequency for inclusion into USCE. The other aim was 
to examine the relationship between acoustic tissue layers and histological layers.  
Surgically acquired tissue was scanned at various µUS frequencies in three different 
orientations with respect to the µUS transducer.  This was done to determine the effect 
layer interface and layer components on acoustic layer generation.  A total of five cases 
were included in this study and tissue was collected exclusively from the colon.  
Neoplastic disease was the reason for all five procedures.  Tissue was collected 
approximately 20 cm from the tumour and presumed healthy.   Three cases (1-3) were 
transmurally scanned with the transducer facing the mucosa (i.e. mucosa to serosa image).  
Microultrasound was able to depict multiple acoustic layers.  Case 1, in particular, was 
able to depict up to 7 acoustic layers with full tissue penetration at 34 MHz.    Case 4 was 
scanned in a novel orientation where the histologic layers were scanned individually.  
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This permitted each layer to generate a signal based on its composition without 
contribution from layer interfaces.  Five acoustic layers were generated at 25 MHz and 
seven acoustic layers were detected at 37 MHz.  Case 5 was scanned transmurally from 
serosa to mucosa at 37 MHz.  Five distinct layers were detected.  Results indicated that a 
frequency ≈35 MHz was suitable for inclusion.  This was due to the high degree of 
superficial tissue detail and both frequencies demonstrated sufficient transmural 
penetration.  The second aim, to further explore the relationship between acoustic and 
histological layers, demonstrated that scanning in various orientations represents a 
practical means of examining the ultrasound-histology relationship.    
Chapter 5 describes the results obtained with a prototype tethered USCE device in vivo 
addressing the feasibility of USCE in the gastrointestinal tract.  The primary clinical 
endpoint of this series of experiments was to determine whether sufficient coupling 
occurred between the capsule transducer(s) and the gut mucosa of pigs to generate an 
ultrasound image.  A total of 18 in vivo experiments were carried out with SonoCap, a 
tethered USCE prototype.  Experiments were conducted in the oesophagus (N=6) and 
small bowel (N=12) in nonrecovery anaesthetised pigs.  Scans were done in both static 
and dynamic capsule modes.  Images were generated of the oesophagus in static and 
dynamic modes indicating sufficient transducer to tissue coupling occurred.  Images were 
also generated of the small bowel in static and dynamic modes indicating capsule 
transducer to mucosa contact.  Similar results were also achieved using an alternatively 
designed USCE prototype from colleagues at Shenzhen University.  Results showed 
coupling between the capsule’s acoustic window and transmural images of the 
oesophagus and small bowel.   Evidence of USCE feasibility was observed in both 
prototype capsules indicating that further research and capsule development is warranted. 
Chapter 6 describes the results of mouse gastrointestinal (GI) inflammation experiments.  
The purpose of these experiments was twofold.  The first objective was to determine 
whether high resolution microultrasound could directly detect leukocyte infiltration 
during GI inflammation.  The second objective was to determine the lowest grade of 
inflammation detectable.  Stage 1 was able to demonstrate the ability of μUS to detect 
overt or severe (i.e. visually perceptible) inflammation at 37 MHz.  Subsequent attempts 
at 37 MHz (Stages 2 and 3) to detect low grades (i.e. mild and moderate inflammation) 
were unsuccessful.  This was despite histopathologic signs of inflammation upon 
microscopic examination.  Further experimentation at 62 MHz was also unable to detect 
lowest grade of inflammation.  Although sever inflammation was detected, low grade 
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inflammation may have been beyond the capabilities of the two frequencies used in this 
series of experiments.  Improved methods of co-registration of the two modalities, µUS 
scanning and histology, would assist with additional experiments of this nature.  
The research described here examined a number of facets in the development of USCE 
in order to fulfil a clinical need for an improved means of diagnosis and management of 
CD and has succeeded in demonstrating areas of potential utility for further study. 
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Chapter 1: Introduction 
 
1. Chapter Introduction 
This chapter provides the motivation, namely clinical need that drove forward the work 
described in this thesis. It also includes an introduction to capsule endoscopy (CE) and 
an overview of ultrasound (US).  An outline of the thesis is provided as well as my own 
contribution to knowledge and a list of publications arising from the work.  
 
1.1. Motivation 
The principal motivation behind this work is to meet the clinical need for improved means 
of diagnosis and management of inflammatory disorders of the bowel, particularly 
Crohn’s Disease (CD), by improving the diagnostic (i.e. imaging) capabilities of CE. 
    
1.1.1. Inflammatory Disorders of the Gastrointestinal Tract 
Enteritis is a nonspecific descriptive term denoting an inflamed state of the small bowel. 
The causes of enteritis are numerous.  Aetiology ranges from infectious causes (e.g. 
bacterial or viral) to autoimmune causes (e.g. Coeliac Disease) and to incompletely 
understood causes (e.g. Inflammatory Bowel Disease).  Although varying from case to 
case, common signs and symptoms can include abdominal cramping and pain, diarrhoea, 
nausea, vomiting and malnutrition. 
CD, or regional enteritis, is a member of the Inflammatory Bowel Disease (IBD) group 
which includes Ulcerative Colitis (UC).  It is a chronic and progressive lifelong disorder 
marked by intermittent periods of quiescence (i.e. remission) and relapse (i.e. flare).  The 
disease may affect any part of the gastrointestinal (GI) tract from mouth to anus, but most 
commonly manifests in the terminal ileum of the small bowel [1].  Figure 1.1 depicts the 
more common anatomic areas affected in the human GI tract. 
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Figure 1.1.  Illustration of the small bowel and colon showing prevalent locations of Crohn’s Disease 
CD) manifestation.  While CD may affect any part of the GI tract, it predominately manifests at the 
terminal ileum.  Image adapted from Mariana Ruiz, public domain. 
CD pathogenesis is incompletely understood but is considered to be multifactorial and 
involve environment (e.g. diet and lifestyle), resident bowel microbes (i.e. Gut Flora) and 
genetics [2].  With regards to the genetic aspect of CD, there is an increased risk of 
development with a positive family history [3].  Several genes and their associated 
products have been identified that contribute to disease development.  Genetic factors 
such as NOD2 and ATG16L1 are involved in innate cell priming and phagocytosis.  Their 
involvement indicates the importance of immunity in the development of CD [2].  
There is no known cure for CD.  Treatment involves pharmaceutical management of 
inflammation and surgical intervention for related complications.  Pharmaceutical 
management involves multiple medications which include anti-inflammatory drugs (e.g. 
steroids and 5-aminosalicylic acid derivatives), immunosuppressants (e.g. methotrexate) 
and biologics (e.g. monoclonal antibodies and Tumour Necrosis Factor inhibitors).  The 
primary therapeutic endpoint is to induce and maintain a lasting remission, to return the 
patient to baseline function and promote adequate nutrition and paediatric growth.  
However, medications used are not without side effects, some of which can be serious, 
particularly in terms of immune suppression and risk of opportunistic infection.  This 
requires balancing therapeutic effect against unwanted side effects to achieve treatment 
goals.    
1 
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Historically indications of treatment success have relied on physician/patient assessment 
regarding the resolution of symptoms.  The CD Activity Index (CDAI) was developed 
and validated in the 1970s to assess treatment efficacy with placebo controlled drug trials 
[4].  The index scores a number of factors (e.g. stools per day, maximum abdominal pain 
and patient wellbeing).  The scores are tallied out of 600 points.  Scores greater than 150 
are considered indicative of active disease with the severity of the grade (i.e. mild, 
moderate and severe) elevating as one approaches 600.  The prominent criticism of CDAI 
is the subjective nature of the assessment.  For instance, abdominal pain caused by CD 
may be over or under reported by patients and affecting overall score.  Furthermore, 
symptoms often do not correlate well with disease activity, with the potential to result in 
over or under treatment.  It is for this reason that the American College of 
Gastroenterology (ACG) no longer recommends symptom resolution as the sole guide for 
treatment [5].  This has led to the development of more objective means of assessment.    
A more objective means involves endoscopic mucosal assessment for signs of ‘mucosal 
healing’.  Mucosal healing is simply defined as the absence of mucosal ulcerations and/or 
erosions [6].  The CD Endoscopic Index of Severity (CDEIS) assesses disease activity 
based on the presence of ulcers (deep and superficial) and area of disease involvement 
which involves ulcerated and non-ulcerated tissue and luminal narrowing [7].  Scores are 
collated for each region examined (e.g. ileum and ascending colon) for final score.  As 
with CDAI, higher scores equate to greater severity.  Although considered more objective 
than self-assessment, image interpretation is subject to observer bias and is reliant on 
assessment of superficial manifestations of disease [8].  Subsurface disease activity 
cannot be assessed without the benefit of tissue biopsy.  Nevertheless achieving combined 
clinical (CDAI <150) and endoscopic remission (CDEIS <3) or ‘deep remission’ is 
associated with improved patient prognosis [9]. 
 
1.1.2. An Emerging Therapeutic Endpoint 
A relatively new treatment endpoint has recently emerged in the medical management of 
CD.  The new endpoint proposes a target of ‘complete remission’ or histological 
remission based on complete resolution of inflammation at the microscopic level [10].  
Currently, the definition of histologic resolution is evolving and has yet to be clinically 
validated. Nevertheless, one generally accepted criteria is the absence of acute 
inflammatory cells in the superficial layers of the bowel [10]–[12].  A systematic review 
4 
 
by Bryant et al concluded that complete remission represented an advanced treatment 
endpoint independent of deep remission [11].  Furthermore, data indicates that achieving 
a complete remission confers improved patient prospects in terms of decreased relapse 
rates, hospitalisations, surgical intervention and neoplastic transformation.   
It has been demonstrated that tissue deemed endoscopically healed can harbour active 
microscopic (i.e. residual) disease [13].  The presence of residual disease can be 
considered a harbinger for early relapse.  According to the European Crohn's and Colitis 
Organisation (ECCO) and the European Society of Pathology (ESP), the presence of 
persistent inflammatory activity in UC is a strong predictor of clinical relapse [14].  
Unfortunately similar data is scarce when examining the same issue in CD.  This is 
partially due to the patchy pan-enteric distribution and the limited reach of 
ileocolonoscopy.  Adding to the data shortage is the invasive nature of endoscopy; it is 
not regularly performed on asymptomatic patients.  As a consequence histologic 
assessment of response is not routine [10], [11].  Nonetheless, two studies did determine 
that between 25% - 37% of cases harboured residual disease activity by histology, despite 
clinical and endoscopic deep remission [15], [16].  Whether this has the same implications 
as UC remains to be fully elucidated. 
Whilst adopting a new treatment target of complete remission has the potential to improve 
patient outcomes, it has yet to be fully embraced.  Hurdles to implementing this strategy 
are numerous, including procedural risk, time and overall cost involved in obtaining and 
processing multiple biopsy samples [17].  In addition to these impediments are the 
technical challenges associated with imaging subsurface pathology, accessing the entire 
GI tract and minimising risk of the imaging modality [11].   
 
1.2. Capsule Endoscopy 
Capsule endoscopy provides a pill based means of examining the entire length of the GI 
tract in an autonomous and non-invasive manner.  While many capsule suppliers exist, 
the market is dominated by Medtronic (formerly Given Imaging).  The following CE 
description is based on the features of the Pillcam™ system.   This consists of capsule, 
abdominal sensor patches and data logger.  The capsule is 11 mm diameter x 26 mm 
length for PillCam SB (small bowel).  Its key feature is the illuminated white light camera 
capable of imaging the luminal surface (i.e. mucosa) of the GI tract (Figure 1.2).  
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1.2.1. History 
The introduction of CE into clinical practice followed the work of Gavriel Iddan and Paul 
Swain reported in 2000 [18].  Capsule endoscopy was particularly attractive for several 
reasons.  First, it provided a means of imaging the entire GI tract including the 
anatomically remote areas of the small bowel.   Other benefits included non-invasive oral 
mode of delivery, no required sedation, relatively benign safety profile and improved 
patient acceptance over conventional endoscopy [19]. 
 
1.2.2. Indications 
Since its introduction, the primary use for CE has become the detection of obscure GI 
bleeding, particularly in the small bowel.  However the role of CE in GI diagnosis and 
disorder management has expanded to include neoplastic disease,  monitoring polyposis 
syndromes and inflammatory disorders such as Coeliac Disease and CD [20].  Other uses 
include determining the causes of abdominal pain and malabsorption [21].  
 
1.2.3. Limitations 
Despite its benefits, currently available CE suffers from a number of limitations including 
the inability to biopsy, poor capsule/lesion localization and dependency on gut peristalsis 
for locomotion [22]. In addition is the restriction to analysis of only the superficial mucosa 
 
Figure 1.2A-C. (A) Front view of a capsule showing the camera and light emitting diodes (LEDs) for 
illumination. The diameter of the capsule is 11 mm. (B) Long axis view (length: 26 mm) of a Pillcam™ 
SB (Medtronic, IE) single camera capsule endoscope (CE). (C) X-ray image of a CE depicting the 
internal components of the capsule. 
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due to CE’s reliance on visible light for imaging [23].  Visible light rays are in the range 
400 - 700 nm and are unable to penetrate beyond the surface of the mucosal layer [24].  
Subsurface pathology cannot be detected, and clinicians are dependent on superficial 
manifestations for assessment.  This opens image interpretation to a number of issues. 
Firstly superficial lesions are often visually obscure and can be variable in appearance 
[2], [25].  Furthermore, there can be visual overlaps between diseases.  Sensitivity also 
declines when assessing low grade disease, as visibility is less overt [26], [27].  All this 
can negatively impact the ability of CE to detect signs of disease. 
 
1.3. Ultrasound Capsule Endoscopy 
Given the superficial only imaging and lack of biopsy capabilities, improvements in CE 
are clinically warranted.  This statement is the position of the American Society for 
Gastrointestinal Endoscopy (ASGE).  The ASGE’s 2013 Technology Status Evaluation 
Report on CE simply states that ‘improvements in technology and techniques are needed’ 
[28].  This is certainly the case for improved assessment of CD especially when 
considering the benefits of complete remission as indicated by Bryant et al [11].  
The development of advanced capsule endoscopes is an area of active research, as 
indicated by the review by Cummins et al on alternative modes of CE based diagnosis 
[29].  One area of CE research and development is the inclusion of microultrasound (µUS) 
forming the basis of Ultrasound Capsule Endoscopy (USCE).     
USCE has the potential to resolve the issue of surface only imaging and mitigate the need 
for tissue biopsy.  Combining the positive aspects of CE (e.g. non-invasive delivery and 
full bowel transit) with µUS imaging has the potential to assess for subsurface (i.e. 
optically occult) pathology.  This capability can conceivably be applied to monitoring 
treatment of CD and thereby advancing the concept of achieving complete remission. 
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Figure 1.3. Schematic of the ultrasound capsule endoscope (USCE) under development in the Sonopill 
programme. The 10 mm diameter by 30 mm long capsule, with spherical ends, is intended to contain 
both ultrasound (component 6) and optical modalities (components 2 and 11). The ultrasound transducer 
(> 25 MHz) permits high resolution subsurface imaging of the bowel wall. Optical modalities include 
both white light imaging (component 11) and fluorescent imaging (component 2).  Additional 
constituents include electronic circuitry (components 3, 4 and 10) and batteries (component 9).  Image 
courtesy of Dr. Vipin Seetohul. 
 
The development and proof of concept of USCE was the remit of the Sonopill Programme 
(EPSRC GR/K034537/2, UK), a multi-institutional, multidisciplinary effort with the aim 
to incorporate µUS and video modalities into a 10 mm diameter by 30 mm long capsule 
(Figure 1.3). 
 
1.4. Diagnostic Ultrasound 
The history of diagnostic US in medicine as a means of non-invasive internal examination 
can be traced back to 1942.  Karl Dussik of Vienna, Austria, first employed US to detect 
cerebral tumours and ventricles of the brain [30].  Dussik’s ground breaking work was 
followed by a number of early pioneers in US diagnostics such as George Ludwig in 
imaging in vivo foreign bodies and gallstones [31].  However it was Ian Donald’s research 
in obstetrics in Glasgow, Scotland, that made US familiar to many expectant mothers.  
His 1958 publication in the Lancet is considered a seminal paper in diagnostic US and 
prenatal care [32].   
Today, US is a ubiquitous presence throughout many disciplines of healthcare such as 
cardiology, urology and gastroenterology.  It is continually praised for its relative low 
cost, safety profile (e.g. use of nonionizing energy), flexibility (i.e. adaptability), and 
resolution (e.g. spatial and temporal).  It is for these reasons that US was considered for 
3 
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inclusion into endoscopic devices for the purposes of endoluminal sonography such as 
endoscopic US (EUS).  The drive behind this development was to improve resolution and 
diagnostic accuracy by removing obstructions (e.g. bone or gas) between the probe and 
target tissue [33].  It is for the same reasons that US was considered for inclusion into CE.  
The rationale was to provide high resolution subsurface imaging whilst being able to 
transit the entire GI tract in a minimally invasive manner [34]. 
   
1.4.1. Concepts in Ultrasound  
Ultrasound waves are produced by the application of an electrical voltage to a 
piezoelectric material such as some specialised ceramics [35]. The electrical signal causes 
a material deformation which generates a high frequency pressure wave.  Sound waves 
are transmitted by an ultrasound transducer (i.e. sound source), which incorporates the 
material, through tissue and echoic reflections return to the transducer. The echoes are 
detected by the transducer and are converted to electrical signals to present tissue images 
based on a time - distance relationship. 
Medical US frequency, measured in MHz, is the number of soundwave cycles per second.  
A cycle is defined as the distance between two soundwave peaks (i.e. wavelength).  By 
shortening the distance between two peaks the frequency of the sound wave is increased.  
There is a direct relationship between wavelength, image resolution and depth of tissue 
penetration.  This concept will be further explored in section 1.4.2 detailing 
microultrasound.  Generating images with US is the result of the interaction of energy 
and the medium in which it travels.  Energy is provided by sound which is almost always 
a longitudinal mechanical (i.e. pressure) wave in medical ultrasonics, in which the 
medium is biological tissue.  
Tissue is a heterogeneous combination of material such as cells, muscle and connective 
components.  These components are organised in such a way as to carry out a specific 
function and are grouped together to form organs such as the GI tract.  Grouping of 
specialised tissue into organs often creates distinctive layers as encountered with skin, 
blood vessels and the bowel wall.  In terms of US, these layers form boundary interfaces 
between different acoustic properties which have the potential to generate an echo (i.e. 
reflection) [36].  As sound travels through tissue, it will encounter a tissue boundary and 
an interface of sufficient difference has the potential to generate a detectable echo.  
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Differences in tissue properties including density and stiffness (i.e. resistance to 
compression) affect the speed of sound propagation through tissue.  
The speed of sound through tissue is, on average, 1.54 mm/µs but can deviate depending 
on the properties of the tissue examined.  For instance, the speed of sound through muscle 
is 1.60 mm/µs and 1.45 mm/µs for fat [37].  The difference in speed can be explained by 
differences in tissue density.  The density of muscle is calculated to be 1.06 g/ml and 
0.9 g/ml for fat [38][39].  This indicates that the sound speed travelling through tissue is 
affected by the physical properties of the tissue, with acoustic impedance a key property, 
comprising the product of density and speed of sound in tissue [35]. Echo generation is a 
result of impedance differences, or acoustic mismatch, from one layer to another.  Sound 
transiting from one layer to another with a high impedance difference will generate a 
bright (i.e. hyperechoic) signal.  Conversely a weak difference will produce a hypoechoic 
(muted) signal and no difference results in a black (anechoic) signal [40]. 
The generation of an echo at the interface is the result of two types of reflection.  The first 
is specular, or mirror like, relative to the wavelength of the ultrasound, and the echo 
returns directly to the sound source.  This is encountered when the material is smooth 
such as a bone shaft and the source is directly (i.e. 90°) above the reflector.  The second 
is type is diffuse reflection and is the result of sound striking uneven boundaries.  The 
returning echo is distributed across a wide range of angles, as opposed to the single angle 
in specular reflection.  This results in multiple echoes of decreased amplitude (i.e. 
strength) returning to the sound source.  Architecturally, the luminal surface of the GI 
tract is characterised as a diffuse reflector due to numerous invaginations and projections.   
Generated echoes will also experience further scattering as a result of tissue composition.  
Soft tissue (e.g. bowel wall) is composed of multiple scattering elements such as collagen 
and muscle fibres [41].  Echoes generated by these elements will occur at multiple angles 
and randomly interact with one another in a constructive or destructive manner.  Echo 
scattering (i.e. backscatter) is influenced by a number of causes intrinsic to the tissue and 
US frequency [41], [42].  Tissue dependent factors include the concentration and 
dimensions of the scatterers (i.e. elements).  Echo scattering also relates to the size of the 
element(s) as scattering occurs where element dimensions are smaller than the 
frequency’s wavelength.  Elements must also demonstrate a degree of acoustic impedance 
difference compared to the surrounding medium to generate an echo.  Scattered echoes 
reaching the transducer contribute to the formation of an US image and result in the 
characteristic texturing of the images referred to as ‘speckle’ [43].  Speckle can provide 
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information regarding the internal make-up of tissue as it is dependent on tissue 
composition [44], [45].  
Only a portion of the original signal is reflected back to the sound source.  As sound 
penetrates successive layers it will undergo attenuation or loss of intensity. In addition to 
reflection and scattering, two other sources of attenuation will be experienced as sound 
transits through tissue.  The first is refraction and it occurs when sound travels between 
tissue types with different speeds of propagation.  The result is deviation of the signal 
path from a straight line.  If detected, the returning echo may be blurred or cause refraction 
artefacts by positioning a structure incorrectly.  The second cause for signal loss is 
absorption, which plays a large role in attenuation [43].  
Absorption refers to the conversion of sound energy in the medium itself, predominantly 
into heat.  Absorption is affected by three primary variables. The first two, viscosity and 
relaxation, are inherent tissue characteristics and the third relates to sound frequency [44].  
Tissue viscosity, as it relates to friction between tissue components, has a direct relation 
to sound absorption.  Increasing tissue viscosity increases the frictional interaction 
between components resulting in in greater absorption and conversion into heat.  
Relaxation refers to the time it takes for a vibrating element to return to a neutral (i.e. 
relaxed) position [46].  A vibrating element has the potential to attenuate sequential sound 
waves if the direction of sound and vibration oppose one another.  Tissue elements with 
long relaxation times will have greater potential to attenuate sound energy.  
Absorption is related to increasing US frequency, with higher frequencies experiencing 
greater absorption. Frequency refers to the number of cycles (e.g. sound waves) that occur 
per unit time.  Thus, increasing frequency increases the number of waves per second. A 
higher frequency also leads to increased absorption due to an increased rate of frictional 
contact between tissue components.  Additionally, there is a decreased likelihood of an 
element reaching a neutral position before the next soundwave arrives.  The result is that 
higher frequencies experience higher attenuation than lower frequencies with a 
consequent decrease in depth of tissue penetration. 
 
1.4.2. Microultrasound 
Microultrasound (µUS) refers to imaging with higher than normal frequencies.  
Conventional diagnostic frequencies generally are in the range of 2 - 20 MHz, with 
frequency choice dependent on the demands of the examination [47].  
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Microultrasound utilises frequencies > 20 MHz.  Examples of microultrasound used in 
clinical practice include intravascular US (IVUS) and Ophthalmology (Figure 1.4).  As 
indicated in Figure 1.4, higher frequency US provides improved resolution in both the 
axial and lateral directions.  As frequency is increased, the US wavelength shortens, 
allowing waves to resolve microstructures too small to generate distinct signals at 
conventional frequencies.  At µUS frequencies, it is postulated that the primary scatterers 
are nuclei of cells [53], [54].  As discussed previously, echo scattering is influenced by 
the quantity (i.e. concentration), dimensions and impedance of the scatterers present and 
the US frequency.  By shortening the wavelength, smaller tissue elements (e.g. cell nuclei) 
present more acoustically and echo generation/scattering will increase with frequency 
[42], [44].  Furthermore, it stands to reason that an increase in white blood cell 
concentration during inflammation can potentially affect the acoustic properties of tissue 
and be detected by US. 
  
1.4.3. Ultrasound and the Gastrointestinal Tract 
US interaction with the layers of the bowel wall produces an image similar to that shown 
in Figure 1.5 [55].  At frequencies of 5 - 12 MHz, the bowel wall demonstrates five 
distinct hyperechoic and hypoechoic layers.  These layers are thought to closely 
correspond to the cardinal histologic layers [55].  The first hyperechoic layer represents 
the mucosa (M) where the epithelium interfaces with the US coupling medium or 
transducer.  The second anechoic signal corresponds with the deeper portion of the M and 
4
 
Figure 1.4A-B. (A) Frequency spectrum of ultrasound used in medial US diagnostic.  (B) Common 
applications of medical US and their relation to the frequency spectrum.  Image adapted from H. 
Rafferty, licensed under the Creative Commons Attribution-Share Alike 2.5 and Maffe et al [48],May et 
al [49], Krill et al [50], Foster et al [51], Silverman [52].  
12 
 
includes the lamina propria (LP) and muscularis mucosae (Mm).  At the interface of the 
Mm and dense collagen rich submucosa (SM), a third hyperechoic layer is present.  The  
 signal transitions into a fourth hypoechoic layer at the muscularis propria (MP).  The 
fifth hyperechoic layer represents the serosa (S) which often contains hyperechoic fat.  
The prevailing hypothesis on ultrasonic layer generation was proposed by Kimmey et al 
and published in 1989 [56].  The authors hypothesised that an US bowel wall image is 
the result of two echogenic sources.  The first echogenic source is an acoustic (i.e. 
impedance) mismatch interface between tissue layers.  The second echogenic source is 
the internal composition of each layer with stiffer materials (e.g. collagen) producing 
hyperechoic reflections.  Despite the frequent referencing of this seminal article, the exact 
relationship between US layers and histology is not universally accepted [57].  The origin 
of the controversy centres on whether the US layers conveniently correspond directly to 
histology or are artefacts created by tissue interfaces which generates an image based on 
the physical properties of the tissue [58], [59].  By the authors’ own admission, US 
technology of 1989 was too underdeveloped to definitely answer the question.  
Furthermore, the limits of image resolution prevented exact correlation of ultrasonic 
layers to histologic layers.     
It has been 30 years since Kimmey’s article was published, yet the controversy still 
remains, despite the advancements in US transducer development [57].  An example of a 
relevant advancement is the application of µUS to the bowel wall.  With µUS, histologic 
sublayers in the form of additional echoic layers become ultrasonically manifest.  
 
Figure 1.5A-B.  Illustration of the bowel wall layers by conventional endoscopic ultrasound frequency 
(A) and histology (B).  Scanning human bowel at frequencies in the range 7 - 12 MHz will produce five 
distinct signals corresponding to the cardinal histologic layers (i.e. Mucosa, Submucosa, Muscularis 
Propria and Serosa).  Hyperechoic (white) and hypoechoic (black) ultrasound signals are thought to arise 
from the interfaces between adjacent tissue layers as well as the internal composition of each layer [2].  
Illustration adapted from P. R. McNally [55].  
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According to Ødegaard et al, higher frequencies can manifest up to four additional US 
layers for a total of nine acoustic layers (Figure 1.6) [36].  At the level of M, the number 
of distinct layers increases from two to four. At conventional frequencies, M generates an 
initial hyperechoic layer at the transducer/tissue interface and a deeper hypoechoic layer 
at the level of the LP.  At higher frequencies (e.g. > 20 MHz) the Mm can generate two 
additional layers to bring the total to four mucosal layers.  The Mm produces a second 
hyperechoic mucosal layer and at the Mm and SM interface, the Mm becomes hypoechoic 
forming the 4th mucosal signal [36], [60].  The SM is hyperechoic until it interfaces with 
the inner circular muscle of the MP, where it becomes hypoechoic.  At conventional 
frequencies the MP tends to be a single uniformly hypoechoic layer.  However, higher 
frequencies can resolve the thin fibrous/neural layer separating the inner circular and 
outer longitudinal muscle as a hyperechoic stripe [36], [60].  The final layer is 
hyperechoic serosa (S).  The echogenic properties of this layer can be further augmented 
with the presence of mesenteric fat. 
Evidence supporting Ødegaard’s conclusion regarding the increase of ultrasonic layers 
have been reported.  For instance, Wiersema described 7 layers when scanning the 
stomach, colon and rectum at 25 MHz [61].  Yoshino and colleagues reported that they 
could visualise 7 US layers from the M to SM using a 30 MHz endoscopic US probe on 
the stomach [60].  However, they concluded that visualisation beyond the SM was not 
possible due to US attenuation by the tissue.  Despite the inconsistencies of the published 
results, it is evident that higher US frequencies can resolve and present additional 
 
 
 
 
 
 
Figure 1.6A-C.  Illustration of the bowel wall layers by conventional 7 – 12 MHz frequency (A), 
histology (B) and high frequency (> 20MHz) ultrasound (C).  Higher US frequencies can enhance image 
resolution and provide a greater level of tissue detail.  Conventional ultrasound typically displays 5 
ultrasonic layers.  High frequency microultrasound can display bowel wall sublayers in the form of 
additional echoic layers for up to 4 additional layers.  This results in a total of 9 layers that can be 
potentially displayed.  Illustration adapted from Ødegaard et al [36].  
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ultrasonic layers.  The enhanced resolution of µUS transducers can potentially assist in 
correlating ultrasonic layers with histologic layers.  
1.4.4. Ultrasound and Pathology 
Tissue undergoing pathologic changes has the potential to have its acoustic properties 
affected.  Merriam-Webster defines pathology as the “the structural and functional 
deviations from the normal that constitute disease or characterize a particular disease” 
[62].  Structural abnormalities associated with disease can alter the tissue architecture and 
compositional elements of tissue.  These in turn may affect US interaction with the tissue 
as image generation is dependent on tissue properties [35].  Pathologic changes have the 
potential to affect a number of echogenic parameters depending on the disease aetiology 
(e.g. cancer or inflammation).  
Potential changes can include acoustic impedance modification through shifts in tissue 
density and stiffness.  Signal attenuation will change as the number of scatterers deviates 
from normal.  It has been demonstrated by Fatehullah et al that µUS is capable of 
detecting premalignant changes in mutant adenomatous polyposis coli (ApcMin/+) mouse 
small bowel [63].  Pathologic changes that accompany ApcMin/+ include the development 
of multiple adenomas (e.g. polyps) which includes cellular proliferation and abnormal 
tissue architecture.  While the authors stated they could reliably image visible polyps with 
µUS, they also concluded that architectural changes could be detected prior to histological 
manifestation.  This was a result of modified acoustic impedance and backscatter 
properties of the tissue. Furthermore, results could be presented in an objective and 
quantitative manner as measurements are based on the physical properties of tissue.  This 
implies data interpretation does not rely solely on subjective interpretation of images. 
These results indicate that µUS can be applied to acute inflammation where the hallmark 
change is massive influx and aggregation of immune cells. 
 
1.5. High Resolution USCE and GI Diagnosis 
Combining high resolution µUS with capsule based endoscopy to form USCE can 
potentially improve the diagnosis and management of GI disorders.  The transmural 
nature of µUS imaging would overcome the surface only imaging capabilities of standard 
CE.  This benefit is particularly well suited for the assessment of treated CD where normal 
(i.e. healed) mucosa, with a normal appearance, can harbor residual disease.  Furthermore, 
full GI tract assessment would provide information on a pan-enteric disorder that is not 
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normally available with conventional endoscopy.  The ability to fully assess disease 
activity would provide clinicians with a means of making better informed management 
decisions.  High resolution transmural imaging would also provide a means of 
determining treatment response at a microscopic level.  This would facilitate the goal of 
achieving a complete response and provide patients with the benefits that accompany 
histological remission.  
Another benefit of µUS is the fast attenuation of high US frequencies as they travel 
through tissue.  The limited penetration makes μUS well suited for imaging the gut wall 
from a USCE perspective.  The decreased depth will maintain a narrow region of interest 
(i.e. the gut wall) as compared to conventional frequencies (Figure 1.7) [65].  The 
advantage of limited tissue penetration is that it may prevent adjacent structures (e.g. 
neighbouring bowel loops) from falsely presenting as oedematous (i.e. thickened) bowel.  
A narrow window permits each bowel section to be evaluated independently for signs of 
disease.  The subject of conventional US assessment of CD will be discussed at greater 
length in Chapter 2. 
 
Figure 1.7.  Schematic of ultrasound resolution and relative tissue penetration depicted from the lumen 
of the bowel outwards. There is a twofold effect as the ultrasound frequency is increased which includes 
enhanced axial and lateral resolution and decrease in tissue penetration as indicated by scaled purple 
arrows. The major advantages of using microultrasound in ultrasound capsule endoscopy (USCE) is high 
resolution transmural imaging which is focused on the bowel wall. Image adapted from Cox et al [64]. 
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1.6. Thesis Outline 
Chapter 2 discusses aspects of the human GI tract gross anatomy and microstructure (i.e. 
histology).  This is followed by a review of GI immune biology including acute 
inflammation and the histology of CD.  Finally, various imaging modalities pertaining to 
CD are reviewed.  
Chapter 3 describes the materials and methods used throughout the thesis.  The materials 
section includes an account of the three models used.  It also provides a description of the 
µUS transducers and associated equipment.  Methods for inducing inflammation, µUS 
scanning and data analysis are included. 
Chapters 4, 5 and 6 present results.  Chapter 4 presents results from µUS scans of 
explanted human tissue experiments.  Chapter 5 summarises the results from the ex vivo 
and in vivo pig experiments in terms of USCE development.  Chapter 6 presents mouse 
results and includes µUS data, histology and comparison of the two methods.  
Chapter 7 discusses the overarching research theme of this thesis and draws conclusions 
from the results of all three models, also outlining possible future research directions. 
  
1.7. Contributions to Knowledge 
The work described in this thesis has contributed to knowledge and development of 
USCE.  
Three tissue types were used to test different aspect of USCE design and function. 
Ex vivo human tissue results indicated that a centre frequency of ≈35 MHz could provide 
high resolution transmural images.  Up to nine acoustic layers were noted on scans, which 
agreed with published results. These results suggested that ≈35 MHz would be suitable 
for inclusion into USCE.  Human tissue scans also provided a means of further examining 
the acoustic-histologic layer relationship.  By scanning the tissue in a nonstandard 
orientation, a novel and independent means of scanning tissue layers was established.  
Scan results were also compared with histology, the gold standard of tissue analysis, for 
the purposes of exploring concepts in virtual biopsy. 
In vivo pig experiments were successfully used to demonstrate that USCE was capable of 
generating bowel images.  It was demonstrated that contact between the tissue mucosa 
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and capsule µUS transducer was achieved.  Contact permitted generation of capsule-
based in vivo µUS images of the GI tract.  Pig experiments concluded with a successful 
demonstration of an early USCE prototype.   
Ex vivo mouse bowel experiments involving induction of GI inflammation showed that 
ultrasound at a frequency of ≈35 MHz was capable of detecting high grade inflammation.  
Further experiments demonstrated that low grade inflammation exceeded the capabilities 
of ultrasound in the range 35 - 62 MHz, thus excluding these frequencies from further 
consideration in future.   
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Chapter 2: The Gastrointestinal Tract 
 
2. Chapter Introduction 
This chapter discusses aspects of the human gastrointestinal (GI) tract beginning with 
gross anatomy.  This is followed by a description of the bowel wall microanatomy (i.e. 
histology).  A review of the immune biology of acute inflammation and how it relates to 
Crohn’s Disease (CD) is introduced.  Finally, the various GI tract imaging modalities are 
reviewed.  
 
2.1. Human Gastrointestinal System 
The human digestive system is an organisation of internal organs and is primarily 
associated with two fundamental tasks: absorption of nutrients and elimination of waste. 
 
2.1.1. Gross Anatomy 
The primary component of the digestive system is the GI tract, a hollow tube that begins 
with the oral cavity (i.e. the mouth) and terminates at the anus.  The alimentary canal is 
grossly divided into sections based on anatomical location. The upper GI tract consists of 
the mouth, oesophagus, stomach and proximal (i.e. superior and descending) duodenum.  
The lower GI tract is comprised of the distal (i.e. horizontal and ascending) duodenum 
and remaining small bowel (i.e. jejunum and ileum).  Forming the terminus of the lower 
GI tract is the colon (i.e. ascending, transverse, descending and sigmoid) which includes 
the caecum, appendix, rectum and anus.  
 
The total length of the GI tract is estimated to be ≈ 5 m for an average healthy adult in 
vivo [66].  Of that total, roughly 2/3 is small bowel.  Length measurements vary between 
individuals and are affected by factors such as diet and lifestyle.  It should be noted that 
the in vivo measurement differs significantly from often quoted lengths such as 8.0+ m 
which are measured post mortem [2].  Differences in measurements have been attributed 
to the loss of bowel tonality following death.  Combining length with the topology of the 
inner surface, the estimated surface area measures ≈ 32 m2 [66], [68].   Roughly 
corresponding with a studio apartment, this is significantly smaller than the tennis court 
area (i.e. 300 m2) traditionally quoted [69].  Nevertheless, 32 m2 represents a substantial 
area when considering microscale modes of examination.  The large surface area aids  
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Figure 2.1.  Gross anatomy of the human gastrointestinal (GI) system which includes the alimentary 
canal and accessory organs.  Image adapted from Mariana Ruiz, public domain. 
 
Figure 2.2.  Illustration of the general microanatomy of the gastrointestinal (GI) tract which extends 
from the lower oesophagus to the rectum.  The luminal mucosal epithelial layer is lined by a simple 
(single) layer of columnar cells.  Included in the mucosa is the underlying lamina propria and muscularis 
mucosae.  Immediately below the muscularis mucosae lies the submucosa.  This is a supporting layer of 
dense connective tissue housing the precapillary vasculature as well as lymphatics and nerves. The 
muscularis propria is formed of two distinct layers of involuntary smooth muscle that runs the entire 
length of the GI tract.  The inner circular layer wraps around the wall circumference and the outer, or 
longitudinal, layer parallels the long axis of the GI tract. The outermost layer is the serosa, a thin 
membrane of connective tissue and cells. Adapted from Frank Boumphrey, Wiki Commons. 
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with digestion and absorption of nutrients by enhancing gut wall-to-chyme (i.e. nutrient 
semifluid) contact.  The complete GI system also includes accessory organs aiding in 
function.  These include the tongue, salivary glands, liver plus bile network and pancreas, 
illustrated in Figure 2.1.    
  
2.1.2. Microanatomy 
The microanatomy or histology of the GI tract is remarkably well conserved throughout 
its length [70].  Cardinal layers, beginning luminally to outermost membrane, are the 
mucosa, submucosa, muscularis propria and serosa.  Figure 2.2 illustrates the general 
arrangement of the bowel wall which includes the cardinal layers and associated 
sublayers. 
The mucosa (M) is comprised of tall columnar cells arranged as a simple (i.e. single) 
continuous epithelial layer.  This arrangement begins at the squamocolumnar junction, or 
z-line, at the gastroesophageal junction (GOJ).  Prior to the GOJ, the epithelial lining is 
arranged in a stratified squamous cell (i.e. multi-layered and flat) manner.  The simple 
columnar epithelium then continues until reaching the anal canal and transitions back into 
stratified squamous epithelia at the pectinate line. The epithelial cells are often referred 
to specifically as enterocytes and colonocytes, denoting their location in the small bowel 
and colon respectively.  Despite different anatomic locations and nomenclature, columnar 
cells demonstrate a similar apical-basal polarity arrangement.  Sublayers of the mucosa 
include the lamina propria (LP), a thin layer of connective tissue and the muscularis 
mucosa, a thin smooth muscle layer delineating the inner border of the mucosa.  
Beneath the mucosa lies the submucosa (SM).  This is a dense connective tissue rich layer.   
The SM contains circulatory vessels such as arterioles and venules.  These form the 
capillary networks of the bowel wall.  Additionally, located in the SM are the nerve and 
lymphatic networks.  The lymphatics begin in the M and muscularis propria (MP) and 
drains into the greater lymphatic system via the mesenteric lymph nodes [71].  The MP 
is formed of two orthogonally orientated layers of involuntary smooth muscle.  The inner 
circular layer runs the entire circumference and length of the bowel wall.  The outer or 
longitudinal layer runs the length of the GI tract. 
Deep to the MP is the serosa (S), a thin membrane of connective tissue and a simple 
squamous layer of mesothelium.  In addition to providing support and lubrication, the 
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serosa blends with the mesentery.  The mesentery serves to tether the bowel to the 
abdominal wall and provides a conduit for vessels, lymphatics and nerves. 
Although the GI tract shares common histologic features, there are morphologic aspects 
unique to each anatomic section as illustrated in Figure 2.3.  General characteristic 
morphology of the small bowel includes villi.  Villi, or finger-like projections, extend into 
the lumen and enhance the absorptive surface area.  Crypts, or short mucosal 
invaginations, are situated between the villi and play a supportive role in epithelial 
renewal.  The GI tract is noted for its rapid turnover of epithelial cells, estimated at 3.48 
± 1.55 days [72].  Crypts house stem cells responsible for maintaining the epithelial lining 
and mucosal integrity.  The bowel surface also possesses numerous folds, called plicae, 
along its length resulting in an irregular and uneven surface. 
The colon also has a similar uneven mucosal surface.  It lacks villi but is dominated by 
crypt invaginations.  The crypts are imbued with numerous mucous secreting goblet cells 
and house basally located stem cells.  Due to the presence of haustra, shallow sack-like 
folds, the colon appears segmented on gross examination. 
 
 
Figure 2.3.  Haematoxylin and Eosin (H&E) sections of the human ileum (L) and colon (R).  Both slides 
illustrate the common features of the gastrointestinal tract including the simple columnar lined mucosa 
(M), submucosa (SM), muscularis propria (MP) and serosa (S).  Additionally, the slides indicate tissue 
specialisation, most notably at the mucosa.  The long finger-like projections, i.e. villi (V), of the ileum 
have the effect of increasing the surface area for the absorption of nutrients. The colon lacks villi but is 
dominated by mucosal invaginations or crypts.  Although present in both sections, the colon is well 
endowed with mucus secreting goblet cells (arrow heads). Slides courtesy of Dr Paul Felts, CAHID, 
University of Dundee. 
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2.2. Gastrointestinal Barrier System 
In order to carry out its absorptive and elimination functions, epithelial cells must 
interface with the external environment.  Thus, the entire length of the mucosa is 
considered in contact with an unsterile environment.  For instance, a major constituent of 
the luminal contents are microbes that colonise the GI tract.  In fact, the human colon 
alone is considered one of the most densely inhabited environments due to the estimated 
1012 organisms per millilitre of luminal contents [73].  As a result, the GI tract represents 
a potential route for microbial insult and invasion. To combat this ever present risk, the 
entire bowel length is endowed with a highly sophisticated and regulated means of 
immune defence, response and tolerance. 
Table 2.1.  Gastrointestinal (GI) tract organisation and function of barrier components. 
The GI tract must transfer material to and from this hostile environment.  To facilitate 
this function, the luminal surface acts as a selective barrier. The selectivity allows for the 
absorption of essential elements whilst simultaneously preventing ingress of noxious 
elements.  Barrier function of the mucosa involves multiple components both inherent to 
the bowel wall itself as well as elements of the immune system (Table 2.1). 
As previously discussed, the epithelium of the mucosa forms a continuous layer.  This 
layer physically prevents ingress of unwanted molecules and microbes.  The major barrier 
component are the apicolateral tight junctions, which securely bind cells to one another 
and facilitate selective transport [74].  Selective transport through the enterocyte barrier 
is achieved through transcellular (e.g. receptor mediated endocytosis) and paracellular 
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routes.  Highly discriminatory, the transcellular route is responsible for the intake of 
nutrients such saccharides and amino acids.  The paracellular route is generally restricted 
to molecules that are <500 kDa and are charged (e.g. cation or anion), which includes 
common electrolytes (e.g. Na+ or Cl-).  Enterocytes are firmly anchored to the underlying 
tissue via the basement membrane [70]. 
Augmenting the epithelial barrier is the luminal mucous layer.  Secreted by goblet cells, 
the mucous layer comprises glycoproteins termed mucin.  Forming a viscous apical 
coating, mucus reduces shear stress on the mucosal layer incurred by passage of luminal 
contents.  Mucus glycoproteins also function as a filter to trap noxious material and 
facilitate its eventual elimination [75].  Simultaneously mucus permits diffusion of 
required nutrients to the epithelial cells [76].   
The barrier role of enterocytes is not limited to a physical barrier role.  They also play an 
important role in communicating with resident immune cells of the GI tract.  
Communication with the immune cells is largely the role of specialised enterocytes called 
microfold cells (M-cells) [77].  These specialised epithelial cells are devoted to sampling 
luminal contents and presenting potential antigens to closely associated immune cells 
[78], [79].  Antigen presentation by M-cells is thought to play a role in inciting an immune 
response or immune tolerance [80], [81].  Enterocytes are also responsible for 
translocating secretory immunoglobulin A (sIgA) into the gut lumen. [82], [83].  The 
function of IgA is to neutralise toxins, inhibit viral attachment, block bacterial mucosal 
adherence and play a role in immune cell activation [84].  Immunoglobulins are 
synthesised by plasmocytes (i.e. mature B-cell) which form a large resident population in 
the LP of the GI tract [85], [86].  
 
2.2.1. Immune Component of the Barrier System 
The overall function of the mucosal immune system of the GI tract is to respond to 
potential pathogenic threats and forms a critical component of the barrier system.  The 
immune system is a highly complex system involving numerous components (e.g. 
antimicrobial molecules, cells and mediators) to protect the host from infection and 
disease.  Complicating the role of the immune component is the need to discriminate 
between beneficial elements (e.g. nutrients and gut commensals) and noxious elements 
(e.g. bacterial or viral pathogens).  The former should not stimulate an immune response 
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(i.e. tolerance) while performing its absorptive function.  However, the latter should elicit 
an appropriate inflammatory response to antigen challenge.   
The primary aim of this thesis is to determine if microultrasound (µUS) is capable of 
detecting an acute inflammatory response. The following sections will focus on aspects 
of the immune system as it relates to an acute inflammatory response. 
 
Gut Associated Lymphoid Tissue 
Due to its close proximity to the external environment, the immune component of the GI 
tract represents one of the largest pools of lymphoid tissue in the human body.  During 
steady state (i.e. healthy) conditions it is estimated that the gut hosts upwards of 70-80% 
of the total lymphocyte population [87], [88]. This equates to a mass of 106 lymphocytes/g 
of tissue [88]. 
Gut Associated Lymphoid Tissue (GALT) is specific to the GI tract and pertains to the 
cellular and structural organisation of the immune component.  It is possible to define 
GALT using different criteria including anatomical compartments and site specific 
mechanisms.  Compartmentally, GALT ranges from highly organised tissue to more 
diffuse elements [89].  Organised elements include lymphoid aggregates that include the 
tonsils, appendix, Peyer’s Patches (PP), mesenteric lymph nodes (MLN) and isolated 
lymphoid follicles [90][91].  Diffuse elements include the scattered resident immune cells 
of the LP.  Mechanistically, GALT may be divided into inductor and effector sites.  
Inductor sites are where naïve lymphocytes are primed for response and include GALT 
sites such as MLNs.  Effector sites represent the major sites of immune cell migration, 
aggregation and antimicrobial activity during the process of acute inflammation.  The 
major effector site of the gut is the LP [92].  
 
Immune Cells   
Immune cells are derived from bone marrow (BM) precursors that migrate to the GI tract.  
Even under healthy conditions, migration is a continuous process in order to maintain 
steady state levels of immune cells.  Maintaining sufficient cell numbers is necessary to  
mount a fast and effective inflammatory response [93]–[95].  The immune component of 
the gut wall consists of cells from the myeloid line (e.g. neutrophils, monocytes, 
eosinophils and basophils) and lymphoid line (e.g. Natural Killer, B and T cells).  Immune 
cells can be further grouped into innate and adaptive components.  The former includes  
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cells of the myeloid and lymphoid lines whilst the latter includes the lymphoid line and 
can be subdivided into humoral and cell mediated immune response (Figure 2.4.). 
The differentiation between innate and adaptive relates to time of response, specificity of 
response and antigenic memory.  Innate cells can mount a rapid but non-specific response 
to a noxious stimulus.  This is due to their ability to inherently recognise pathogens or 
damaged tissue.  The adaptive, or acquired, immune arm is able to mount a specific 
antigenic response.  However, antigen specificity requires time to develop, and results in 
delayed response as opposed to the rapid response of the innate component.  While the 
innate response can be measured in hours, a naïve adaptive response requires days.  
Notably, the adaptive immune component possesses antigen memory so that subsequent 
exposure to a specific antigen elicit a faster response [29].   
  
Innate Immune Cells 
Cells of the innate arm are intrinsically able to recognise external threats and internal 
damage.  This is facilitated by Pattern Recognition Receptors (PRR).  These germ-line 
encoded receptors allow innate cells to rapidly recognise and respond to an insult.  These 
receptors are not only expressed by innate immune cells but also epithelial cells such as 
M-cells [96].  Several classes of PRRs exist and are grouped according to cellular location 
 
Figure 2.4.  The immune component of the gut wall consists of cells of both innate and adaptive lines.  
These cell lines are derived from bone marrow progenitor cells and include lineages from the myeloid 
line (neutrophils, monocytes, eosinophils and basophils) and lymphoid line (Natural Killer, B and T 
cells).  Immune cells can be further divided by grouping cells into innate (*) and adaptive components 
(#). The adaptive component can be subdivided into cell mediated (#) and humoral (#) responders.  Image 
by Mikael Häggström, Public Domain.  
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(e.g. membrane or cytosolic), ligand and function [97].  These receptors can recognise 
and bind to conserved structures on microbes.  Conserved structures include bacterial 
lipopolysaccharide (LPS), flagellin and nucleic acids of viral and bacterial origin.  
Collectively, microbial associated PRR ligands are termed Pathogen-Associated 
Molecular Patterns (PAMPS).  Well characterised examples of PRRs are Toll-Like 
Receptors (TLR).   Upon binding to a recognised ligand, transmembrane TLRs will 
dimerise and activate transcription pathways necessary for initiating the inflammatory 
process [98]. 
In addition to exogenous ligands, there are endogenous danger signals associated with 
tissue damage.  Such molecules are Damage-Associated Molecular Patterns (DAMPs).  
Released during periods of cellular stress (e.g. infection) or damage (e.g. necrosis), 
DAMPs represent either intracellular molecules (e.g. histones) or extracellular matrix 
fragments [99].  As with PAMPs, DAMPs are highly conserved molecular structures and 
can be recognised by PRRs.  Under non-inflammatory (i.e. steady state) conditions, 
DAMPs are normally sequestered from interaction with PRRs to prevent inappropriate 
initiation of the inflammatory process [99].  During periods of cell stress (e.g. infection), 
DAMPs are released permitting PRR-DAMP interaction and eliciting an immune 
response by activating immune cells [100].    
 
Mononuclear Monocytes 
Mononuclear monocytes include circulating undifferentiated monocytes, tissue resident 
macrophages and dendritic cells.  The latter two represent mature and tissue fixed 
monocyte subsets found in a number of epithelial linings (e.g. skin, respiratory and GI).  
Tissue-specific residential macrophages/dendritic cells are often referred to with 
specialised names such as Kupffer (Liver) and Langerhans (Epidermis) cells. This 
indicates that resident monocytes can differentiate into tissue specific subsets according 
to location and function [101].  
Monocytes are located along the length of the GI tract with the highest concentration in 
the colon [102].  Histologically, the highest density of monocytes is found in the LP [103].  
This arrangement relates to their surveillance function against barrier breaches and early 
responding effector cells. Despite their varied phenotypes, monocytes are considered 
specialised (i.e. professional) antigen presenting cells (APC) functionalised to display 
antigens to other cells (e.g. effector or regulatory cells).  This is mediated with Major 
Histocompatibility Complex (MHC) II, also known as Human Leukocyte Antigen (HLA) 
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II [104].  Presentation of antigen is predominately achieved through phagocytosis of 
endogenous (e.g. cellular debris) or exogenous (e.g. bacterial components).  Following 
engulfment, the antigen is processed and presented at the cell surface bound to MHC II 
and associated with co-stimulatory molecules such as CD40 and B7 [10].  Antigen 
presentation allows APCs to interact with other immune cells including that of adaptive 
arm.  In this regard, APCs function as a link between the two immune system components. 
 
Neutrophils 
Polymorphonuclear (PMN) leukocytes include neutrophils, eosinophils and basophils.  
Neutrophils represent the most abundant white blood cells in circulation and typically 
make up to 70% of cells in a complete blood count (CBC) [105].  
Upon maturation, neutrophils are released from the bone marrow into the circulatory 
system.  They have a short half-life of approximately 6 - 8 hours and a daily turnover rate 
of 5×1010 –10 ×1010 cells/day at steady state [106].  During their short lifespan, 
neutrophils will remain in circulation until encountering one of two fates.  Upon reaching 
unstimulated senescence, neutrophils will undergo apoptosis and are cleared by 
macrophages in the liver, spleen or bone marrow [106].  The short life-span is thought to 
control cells numbers and, in turn, control the potentially destructive nature of neutrophils 
[106], [107].  Notably, neutrophils are considered rare in non-inflamed tissue [87], [108], 
[109].  For instance, it is estimated that < 5 neutrophils per high power field (hpf) reside 
in the appendix under baseline (i.e. healthy) conditions [110].  The alternate fate of 
neutrophil activation, migration (i.e. tissue accumulation) and antimicrobial mechanisms 
will be discussed in the next section. 
 
2.3. Inflammatory Response 
An inflammatory response is a biological response to noxious stimuli mediated by the 
immune system (Figure 2.5).  It is a complex and highly coordinated process involving 
the previously discussed immune cells.  The purpose of an immune response is to rapidly 
neutralise and remove the insult.  The final endpoint is to return to the system to baseline 
form and function upon resolution. 
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The process of inflammation can be described as either acute or chronic.  An acute 
response induces a rapid proinflammatory cascade of events.  This results in an initial 
swift influx and accumulation of innate immune cells at the site of injury.  The duration 
of an acute response is usually measured in days. A chronic inflammatory response is a 
 
 
Figure 2.5.  Stages of the acute inflammatory process involving cells of the innate and adaptive immune 
system.  The stages involved are 1. Initiation, 2. Maintenance and 3. Resolution.  Initiation begins with 
a barrier breach in the epithelial lining.  Sentinel resident macrophages detect conserved molecular 
patterns originating from luminal microbes (PAMPs) or endogenous molecules released due to tissue 
damage (DAMPs).  Activated macrophages will release proinflammatory mediators such as Tumour 
Necrosis Factor Alpha (TNF-α) and Interleukin-1Beta (IL-1β).  The mediators will result in vascular 
endothelial cell upregulation of adhesion molecules and increased permeability.  This step is necessary 
for the recruitment of circulating immune cells such as neutrophils, monocytes and lymphocytes.  Cells 
will extravasate from circulation and migrate along the mediator gradient to the site of injury.  The 
accumulation of immune cells will continue during the maintenance stage until the immunogenic 
stimulants are cleared.  Resolution occurs with clearance of proinflammatory stimuli including 
endogenous and exogenous debris.  Monocytes/macrophages will then clear spent neutrophils and 
release proresolving mediators such as Transforming Growth Factor-β (TGF-β) and IL-10.  These 
mediators serve to diminish further recruitment by down-regulating adhesion molecules and up-
regulating stromal cell activity. Activation of stromal cells (e.g. fibroblasts) initiates the repair process 
with the intention of returning affected tissue to a functioning baseline condition. 
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prolonged process that may range in duration from months to years [111].  Persistent 
immune activation is often attributed to failure to remove immunogenic stimuli as 
resolution of inflammation is dependent on clearance of immunogenic stimuli [112].  The 
continual or repeated activation of the immune system is, in itself, a pathologic condition 
as illustrated by CD [113]. 
 
2.3.1. Acute Inflammation 
An acute inflammatory response is classically defined as the remit of the innate arm.  It 
is characterised by rapid onset and short duration (Figure 2.6).  The stages involved can 
be described in terms of initiation, maintenance and resolution with characteristic timing 
of immune cell type infiltration at the LP effector sites [90]. 
 
 
 
 
 
Figure 2.6.  Relative influx and aggregation of immune cells measured in days post barrier injury.  
Neutrophil influx can be measured in minutes after injury and accumulation will peak by 24 – 48 
hours afterwards.  Monocytes will then follow in a second wave as a result of neutrophil release of 
chemoattractants.  Second wave migration begins almost immediately post initiation and continues 
for an extended period of time. By the conclusion of the inflammatory response monocytes represent 
the predominate cells.  Monocytes will interact with the adaptive arm, resulting in B- and T-cell 
priming, activation and differentiation.  Activated lymphocytes will then infiltrate and accumulate at 
lamina propria effector sites.  Adapted from Witte and Barbul [114]. 
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Initiation 
Initiation begins when an exogenous or endogenous stimulus is encountered and 
phagocytosed by sentinel tissue macrophages.  This triggers the recruitment of circulating 
monocytes and neutrophils as well as activation and expansion of the adaptive immune 
system.  
 
Activation of sentinel tissue fixed macrophages results in expression and release of 
proinflammatory mediators that are responsible for further leukocyte recruitment.  
Among the first effects of the proinflammatory mediators (e.g. TNF-α, IL-β) is activation 
of post capillary endothelial cells (ECs).  Activated ECs release chemoattractants 
responsible for immune cell recruitment.  These molecules promote and direct immune 
cell migration to the site of injury.  The gradient establishes a ‘homing signal’ to attract 
and recruit circulating leukocytes.  Stimulation of ECs will also result in upregulation of 
adhesion molecules necessary for the arrest and migration of immune cells into the 
affected area [115]–[117].  Another notable effect of EC activation is increased vascular 
permeability to facilitate leukocyte extravasation.  This also results in net fluid movement 
into the injured area causing the familiar swelling (i.e. oedema) that accompanies 
inflammation [118]. 
During periods of inflammation, the circulating neutrophil numbers can be increased 
upwards of 10-fold [119].  This is achieved by releasing bone marrow reserves into 
circulation and enhancing bone marrow production [120].  During the initial phase of 
inflammation, neutrophils migrate and accumulate in the area of invasion/injury.  This 
effect occurs within minutes and peaks by 24 – 48 hours [121].  Peripherally circulating 
PMNs detect and follow a chemical gradient through chemotactic navigation.  Upon 
localising and arresting at the site of injury, PMNs extravasate from circulation and 
migrate to the LP where neutrophils aggregate and cluster in a process called ‘neutrophil 
swarming’ [122].  These swarms may be temporary (10 - 40 minutes) or persistent (> 40 
minutes) in nature.  Cell numbers are in the range approximately 10 - 150 neutrophils for 
temporary swarms and > 300 neutrophils for persistent swarms.  
Because of experimental limitations, delineating the in vivo spatiotemporal dynamics of 
swarming remains poorly understood [123].  This includes calculating cell density per 
swarm.  However it is known that neutrophils are required to reach a critical neutrophil 
concentration (CNC) to control bacterial growth [124].  Li et al estimated that a CNC of 
4 x 106 - 8 x 106 neutrophils/ml at the dermis is necessary for bactericidal activity.  
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Cybulsky et al demonstrated a 150 fold increase in neutrophil population within 4 hours 
of intradermal injection into antigen rabbits [125].  Although the two aforementioned 
experiments are limited to the dermis, they illustrate the rapid accumulation of neutrophils 
at the site of insult during the process of inflammation.  
During this phase, monocytes interact with the adaptive arm resulting in B- and T-cell 
priming, activation and differentiation [126].  Post activation, antigen specific B- and T- 
lymphocytes undergo selection, clonal expansion and proliferation [127].  Clonal 
expansion is estimated to occur by a factor of 2 - 4 times within a 24 hour period.  
Completion of expansion is estimated to take 4 - 5 days explaining the delay in the 
adaptive response.  It is estimated that a single antigen specific cell will gives rise to a 
thousand or more daughter clones [84], [127], [128].  Activated lymphocytes then migrate 
and accumulate at injured LP effector sites [92]. 
 
Maintenance 
Upon establishing an initial response, the immune system will enter the maintenance 
phase.  During this phase the response is amplified through positive feedback 
mechanisms.  Arriving neutrophils undergo a transcriptional burst, resulting in de novo 
synthesis and release of proinflammatory cytokines such as IL-8 [129], [130].  This results 
in further neutrophil recruitment as well as recruitment of circulating monocytes.  The 
second wave of monocyte infiltration has important repercussions in determining the 
outcome of the inflammatory response.  Upon arrival, monocytes will differentiate to 
become either proinflammatory (Classical M1) or immune suppressive (Alternative M2) 
[131].  Principally, proinflammatory monocytes function to amplify and sustain the 
immune response through further neutrophil/monocyte recruitment [132]. The latter 
suppressive role will be discussed in the section on resolution.  
Initially, neutrophil migration to the site of injury exceeds monocyte numbers.  However, 
second wave migration begins almost immediately post initiation and continues for a 
longer period of time [133].  By the conclusion of the inflammatory process monocytes 
represent the dominant cell type in a lesion.  This phenomenon is most likely explained 
by the role of monocytes in all stages of inflammation including the cessation of 
inflammation [102].  The dynamics of the maintenance phase are linked to antigen load 
and will continue until antigen clearance has been achieved. Upon elimination of the 
stimulus, the immune response enters the resolution phase.         
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During the inflammatory response, nonspecific microbial clearance is achieved via a 
number of different mechanisms (Table 2.2).  Neutrophil antimicrobial mechanisms 
include antigen phagocytosis, oxygen radical release, antimicrobial molecules (e.g. 
proteolytic enzymes) and the formation of neutrophil extracellular traps (NETs) [129], 
[134].  The synthesis and release of reactive oxygen species (ROS) occurs during 
‘oxidative burst’.  Catalysed by NADPH oxidase and myeloperoxidase (MPO), oxidative 
burst results in production of destructive oxygen radicals such as superoxide anion (O2
−), 
hydrogen peroxide (H2O2), and hydroxyl radicals (HO∙).  
As summarised in Table 2.2, neutrophils possess ample means of bacterial elimination 
and are well suited to their primary role.  However, these antimicrobial ‘weapons’ are 
nonspecific and pose a threat to host tissue.  Collateral host tissue damage has been linked 
to the oxygen radicals and proteolytic enzymes [121].  
ROS are inherently unstable and biochemically indiscriminate.  These molecules will 
damage exogenous and endogenous molecules such as lipids, proteins and nucleic acids.  
This can result in self-cell death via apoptotic or necrotic pathways due to oxidative stress 
[136]–[138].  Protective enzymes such as catalase and glutathione peroxidase can 
counteract the deleterious effects of ROS.  Further protection comes in the form of free 
radical scavengers (i.e. antioxidants), which include glutathione and diet derived 
 
 
Table 2.2.  Selected neutrophil antimicrobial products implicated in collateral tissue damage. During the 
inflammatory response, neutrophil killing of microbes is achieved via a number of different mechanisms.  
Primary mechanisms include phagocytosis and release of proteolytic enzymes.  During oxidative burst 
neutrophils will synthesise and release a number of reactive oxygen species (ROS).  Both proteolytic 
enzymes and ROS are involved in damage to host (i.e. self) tissue due to the non-specific nature of the 
anti-microbial products.  Adapted from Wilgus [135] and Winterbourne [136]. 
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antioxidants (e.g. vitamins A, C and E).  However, during an inflammatory state, such 
protective measures may be overwhelmed, tipping the balance to favour oxidative stress 
induced damage.  This imbalance can result from an excessive or prolonged inflammatory 
response [64], [69].  
  
Many of the enzymes released by neutrophils are nonspecific and can attack endogenous 
as well as exogenous targets.  Included amongst the proteolytic enzymes are serine 
proteases and matrix metalloproteases (MMP).  These proteases will degrade the 
supporting structural extracellular matrix (ECM) and basement membrane [135].  
Although this phenomenon has been implicated in aiding neutrophil migration to wound 
sites, protease activity can also result in structural damage.  This damage can prolong 
inflammation and delay re-epithelialisation and wound healing [135], [139], [140].  
Protease inhibitors such as α1-antitrypsin and secretory leukocyte protease inhibitor can 
limit such damage but, during inflammation, the balance favours proteolytic activity.    
Also involved in the generation of collateral tissue damage are NETs.  Neutrophils release 
a network of chromatin composed of DNA, histones and antimicrobial molecules 
including neutrophil elastase, myeloperoxidase and cathepsin G [141].  The primary 
purpose of NETs are to trap microbes, prevent bacterial dissemination and localise the 
neutrophil response [142].   Evidence suggests that NETs may provide means of 
prolonged exposure to self-antigens leading to prolongation of an immune response [143].  
Current opinion holds that NETs are involved in a number of chronic inflammatory 
pathologies such as vasculitis, Systemic Lupus Erythematosus and IBD [140], [144].   
 
Resolution 
The purpose of resolution is to return inflamed tissue to baseline form and function.  
Immune resolution depends on the interplay between different mechanisms.  This 
involves suppression of proinflammatory stimuli, arrest of cell recruitment, and reduction 
of effector site immune cells.  The principle effectors of resolution are monocytes.  During 
the second wave of monocyte migration, arriving monocytes can differentiate into 
alternative (M2) macrophages and function as immune suppressors.  This represents a 
key step towards resolution as M2 cells function in multiple pro-resolution roles [131].  
Phagocytic clearance of proinflammatory stimuli represents a critical step as elimination 
of proinflammatory stimuli favours a conclusion of inflammation [145].  Debris, in the 
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form of exogenous (e.g. microbial) and endogenous (i.e. self) material, represents a 
proinflammatory stimuli and removal is considered the primary driver towards resolution 
[146].  Furthermore, elimination of accumulated neutrophils represents another important 
step towards resolution.  Spent neutrophils that have performed their antimicrobial 
function will undergo intrinsic programmed cell death (i.e. apoptosis).  The process of 
apoptosis, as opposed to necrosis, sequesters proinflammatory debris from immune cell 
recognition.  Efficient removal of antigen laden cells and fragments reduces the potential 
for inappropriate continuation of inflammation.  This requires monocyte mediated 
clearance via specific phagocytic process.  This non-inflammatory process is termed 
efferocytosis.  What distinguishes efferocytosis from phagocytosis is its role in inducing 
monocyte switching to a proresolution phenotype [145].  Proresolution M2 monocytes 
secrete a host of anti-inflammatory mediators and as the M2 population increases, the 
anti-inflammatory gradient favours resolution over maintenance.  
Suppressive M2 monocytes also secrete proresolving mediators (e.g. IL-10) which 
function to arrest further cell recruitment and stimulate reduction of accumulated immune 
cells [131].  Neutrophil apoptosis may also be initiated extrinsically by M2 monocytes 
with the release of Fas ligand (FasL) [131].  This acts in concert with neutrophil up-
regulation of death receptors such as the membrane bound Fas Receptor (FasR).  Binding 
of FasR with FasL results in inducing neutrophil apoptosis [147].  Further immune cell 
suppression occurs with down regulation of co-stimulatory molecules on M2 monocytes.  
Without costimulatory molecules, such as B7, interaction between monocyte MHCII and 
corresponding B or T-cell receptors is incomplete.  This results in an anergic (i.e. 
nonresponsive) state and induction of apoptosis [146].  Finally, M2 monocytes also 
facilitate the induction of tissue repair by stimulating resident stromal cells with 
mediators, such as Transforming Growth Factor-β and Vascular Endothelial Growth 
Factor (TGF-β and VEGF respectively) [145], [148].  Activation of these cells (e.g. 
fibroblasts) initiates the repair process with the intention of returning affected tissue to 
normal conditions.        
Failure to resolve acute inflammation in a timely manner has serious implications for 
continued neutrophil mediated tissue destruction and failure to resolve.  The inability to 
resolve inflammation in a timely manner has been implicated in a number of chronic 
inflammatory diseases including Crohn’s Disease [140].  
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2.4. Histopathology of Crohn’s Disease  
CD is a lifelong inflammatory bowel condition involving the entire GI tract.  It is marked 
by periods of disease quiescence and flare.  During periods of relapse, an acute 
inflammatory response is superimposed on a chronic inflammatory state.  Distinguishing 
the two inflammatory types has important implications for disease management [10], 
[149]. 
Macroscopically, CD manifests in a heterogeneous manner but has a number of 
stereotypical features (Figure 2.7).  Early mucosal disease may present as normal tissue 
or manifest with multiple small (1 - 2 mm Ø) superficial ulcers.  These ulcers may 
coalesce to form linear, or serpiginous, ulcers separated by oedematous tissue.  This 
combination results in the classic ‘cobblestone’ appearance of an affected area.  
Commonly CD manifests in patchy, or discontinuous, lesions with defined borders.  
Affected areas may be separated by areas of mucosa of normal appearance, resulting in 
‘skip’ lesions [150].  Other macroscopic features include luminal narrowing due to 
fibrosis (i.e. strictures), abscesses and fistulae.  Fistulae are abnormal passages that may 
connect two body parts (e.g. small bowel to colon) or end blindly [151].  Also typical of 
CD is the phenomenon of ‘fat wrapping’, with mesenteric fat encircling an affected area 
[152]. 
Histologically, CD has a number of key features that are a result of the chronic and acute 
aspects of the disease (Figure 2.8).  A distinguishing feature is the transmural nature of 
inflammation [153].  Inflammation associated with CD extends from mucosa to serosa, 
with immune cells present in all layers of the bowel wall [14].  Chronic features are the 
result of long standing disease involving immune cell organisation, tissue remodelling 
and architectural distortion [154].  
A hallmark histologic sign of long-standing CD is the presence of non-caseating 
granulomas.  Granulomas are defined as node-like aggregations of activated 
monocytes/macrophages surrounded by lymphocytes [111].  The non-caseating 
description indicates that they do not have a necrotic core, as is the case with tuberculosis 
granulomas.  The patchy distribution of CD presents with focal lesions.  These are 
characterised by increased LP cellularity consisting of aggregated lymphocytes.  
However, given the transmural nature of the disease, immune cells are not restricted 
superficially and can be found in deeper layers [14].   
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Active or ‘acute-on-chronic’ disease is characterised by recruitment and accumulation of 
innate immune cells (e.g. neutrophils and monocytes) superimposed on the chronic 
components (e.g. fibrosis) [155], [156].  Active CD is defined by a characteristic pattern 
of neutrophil accumulation which includes cryptitis and crypt abscesses [14], [152], 
[108].  Cryptitis is defined as neutrophil infiltration into the epithelium crypts.  A crypt 
abscess is the presence of neutrophils in the lumen of affected crypts.  Further diagnostic 
criteria includes neutrophil associated epithelial damage in the form of erosions or 
ulcerations.  Neutrophils may also accumulate in the LP.  The International Organisation 
of Inflammatory Bowel Disease defines the absence of neutrophils in the LP as indication 
of histologic remission [11], [108].  However, assessment of disease activity by LP 
infiltration lacks the reliability or reproducibility of cryptitis and crypt abscesses [14], 
[102].  
 
Figure 2.7.  Typical macroscopic features associated with Crohn’s Disease.  Mucosal changes include 
multiple serpiginous, or linear, ulcers, resulting in a cobblestone appearance. A common gross 
characteristic of CD is the patchy, or discontinuous, appearance of the disease. Affected areas may be 
separated abruptly by areas of mucosa of normal appearance, resulting in ‘skip’ lesions. Due to fibrotic 
deposition, the lumen will experience progressive narrowing.  Deeper pathology includes transmural 
infiltration of immune cells.  Transmural defects in the form of abscesses and fistulae are also seen.  Not 
shown is fat ‘wrapping’ where the mesenteric fat will encircle an affected area.  Adapted from Rubin 
Essential Pathology [157]. 
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Focal architectural changes that accompany chronic CD are important criteria for 
diagnosis [14], [159].  Ileal mucosal changes include villus distortion and crypt 
irregularity.  Crypt irregularity is defined as non-parallel crypts, compromised or variable 
diameters (e.g. dilated crypts), with branches of decreased length [160]. 
 
2.5. Clinical Imaging 
The diagnosis and monitoring of CD involves a number of modalities including clinical 
assessment, laboratory studies, pathology and imaging.  Imaging involves the use of both 
external (i.e. radiology) and internal (i.e. endoscopy) means.  Both approaches play an 
important role in establishing a diagnosis, measuring disease extent, detection of 
complications and determining disease activity.  Furthermore, imaging disease activity 
assists in guiding management decisions and assessing response to medical therapy [5].  
 
2.5.1. External Modalities 
Current accepted means of non-invasive, external imaging of bowel inflammation include 
the use of standard X-ray, computed tomography (CT), magnetic resonance imaging 
 
 
Figure 2.8A-B.  Haematoxylin and Eosin (H&E) slide of the ileum from a 58 year old female diagnosed 
with CD.  The left slide represents a low magnification view.  The right slide is a higher magnification 
of the left slide (dashed green box).  Histology demonstrates examples of ‘acute on chronic’ disease that 
result in a small bowel obstruction requiring surgical intervention.  Notable features include transmural 
inflammation by mixed innate and adaptive immune cell types. The LP demonstrates focal areas of 
enhanced cellularity (chevrons).  There is also considerable crypt irregularity including non-parallel 
crypts with variable diameters.  There are multiple non-caseating granulomas (asterisks) i.e. collections 
of monocytes / macrophages surrounded by lymphocytes.  They do not contain a necrotic core and are 
considered a hallmark feature of CD.  Indications of active disease are the neutrophil associated mucosal 
erosion (arrows), cryptitis and crypt abscesses (arrow heads).  Slide from Virtual Pathology at the 
University of Leeds [158]. 
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(MRI) and conventional ultrasound (US) [161].  Each modality has advantages and 
disadvantages (Table 2.3).  There is a continued debate about which offers the most 
efficacious means of assessing disease.  To date, no single modality has emerged as 
significantly superior to the other [162].  Regardless, it is clear that cross-sectional 
imaging of the bowel wall is the most effective means of disease assessment [163].  The 
primary advantage of cross-sectional imaging is evaluation of the transmural extent of 
inflammation [164].  Other advantages include improved imaging of associated 
complications (e.g. abscess and fistula) and detection of extraluminal signs (e.g. fat 
wrapping and lymph node involvement) [165].  Modalities capable of cross-sectional 
imaging of the bowel wall include CT, MRI and US and have largely replaced standard 
X-ray imaging [166]. 
In terms of overall CD assessment, which includes mural and extra luminal 
manifestations, contrast enhanced CT offers good sensitivity and specificity.  This is 
particularly true for bowel obstruction (e.g. fibrotic stenosis) where sensitivity is in the 
range 81 - 94% and specificity is 96% [166].  However, sensitivity and specificity decline 
to 81% and 88%, respectively, when assessing low grade (e.g. early) disease activity 
[167].  This is due to the lack of sufficient spatial resolution of CT to detect early 
pathology at the mucosal level [163], [164], [166].  For example, early disease features 
(e.g. superficial ulcers) are not readily detected, limiting the use of CT in detecting low 
grade disease activity.  Furthermore, the primary diagnostic criteria of inflammation is 
bowel wall thickening of greater than 3 mm [168].  Thickening is a nonspecific 
phenomenon and is associated with other bowel pathologies such as infection and 
neoplasms [169]. Furthermore, bowel thickening is not a feature of early active disease 
[163].  Other mural signs of inflammation fat halo sign which is generated by fat 
deposition in the submucosa, however, this sign may not be specific to IBD and maybe, 
in some instances, related obesity [170], [171]. 
Other limiting factors are related to bowel preparation, contrast enhancement and the 
nature of CT image generation.  Pre-examination bowel preparation involves fasting 
and/or laxatives to achieve a clean bowel [164].  Furthermore, satisfactory bowel lumen 
patency is necessary to avoid collapsed bowel loops which can mimic pathologic signs 
(e.g. wall thickening) [164].  To improve luminal imaging capabilities, CT uses both oral 
and intravenous (IV) contrast.  Oral contrast requires ingestion of large volumes 
(1 - 1.8 L) and can be poorly tolerated and uncomfortable due to bowel distension [172].  
A further limitation of CT regards the use of ionising radiation giving a cumulative  
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radiation dose and increased risk of cancer.  This issue is particularly salient for paediatric 
patients where the long term nature of the disease and repeated examinations enhances a 
pre-existing risk of neoplastic disease [173].  It is for these reasons that the European 
Crohn´s and Colitis Organisation (ECCO) recommends CT for the diagnosis of acute 
complications only (e.g. fibrotic obstruction) [165], [174]. 
MRI is similarly capable of cross-sectional imaging in addition to assessing extramural 
disease.  Furthermore, the reported sensitivity and specificity, 85% and 91%, respectively, 
are comparable to CT [167].  The excellent soft tissue contrast of MRI permits enhanced 
discrimination between pathology and healthy tissue [164], [166].  Assessment of CD 
activity is initially based on non-specific bowel thickening (>3 mm).  Further evaluation 
is based on T2 imaging of bowel wall for signs of acute inflammation [175].  Detection 
can be improved with oral and IV contrast.  Increased disease activity is thought to 
correlate with the presence of extravasated gadolinium (Gd) contrast into the bowel wall 
[163].  However, there is some indication that this relationship only offers a weak to 
moderate indication of disease activity [176].  Nevertheless, the limits of spatial 
resolution prevent reliable visualisation of early stage disease [164].  Also, MRI uses oral 
contrast in large volumes (≈ 1.5 L) to improve detection by distending the bowel lumen.  
As with CT, this is an important step in preventing misleading signs due to collapsed 
bowel [163].  The primary advantage of MRI over CT is the lack of ionising radiation.  
Table 2.3.  Summary of the advantages and disadvantages of imaging CD by external means. 
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The combination of satisfactory diagnostic capabilities and lack of ionising radiation has 
resulted in ECCO recommending MRI as the preferred imaging modality for repeated 
scanning [165], [174].  
Transcutaneous abdominal sonography (TABS) is another means of assessing disease.  
Specificity and sensitivity for the detection of mural inflammation are 75% - 94% and 
67% - 100% respectively [177].  The large range variation is attributed to both anatomic 
location of disease and inter-operator variability [166], [167].  It has been noted that 
diagnostic accuracy diminishes when imaging deep bowel anatomy (e.g. rectum and 
upper small bowel) [178].  Greatest accuracy is possible when the disease manifests in 
the terminal ileum [166].  Bowel thickening is again the primary criterion used for 
assessing bowel inflammation.  Supporting evidence includes loss of bowel wall 
hyper/hypoechoic stratification, presence of ulcers and reduced bowel motility [163].  
Increased mural vascularisation that accompanies acute inflammation.  This maybe 
imaged with doppler US, semi-quantified and scored with the Limberg score.   Tissue is 
graded (i.e. 0-4) based on thickening, wall stratification and flow [179], [180].  In order 
to permit sufficient tissue penetration for imaging the bowel, US is used in the frequency 
range 3.5 - 7.5 MHz [163], [181].  However these relatively low frequencies reduce 
spatial resolution and inhibit TABS assessment of low grade disease activity [163], [182].  
Nevertheless, the wide availability of US, low cost and lack of ionising radiation has led 
ECCO to recommend the use of TABS in the initial and emergent assessment of CD 
[174].  
 
2.5.2. Internal Modalities 
Endoscopy represents a more invasive but direct means of evaluating disease activity 
(Table 2.4).  The combination of direct mucosal visualisation, biopsy capabilities and 
delivery of therapeutics has made ileocolonoscopy the gold standard examination [183].  
Other endoscopic methods include capsule endoscopy (CE), deep small bowel 
enteroscopy and upper endoscopy [165], [183], [184].  The most common mode of 
visualisation is white light imaging (WLI).  The major disadvantage of this mode is the 
limitation to superficial mucosa assessment only [185].  Subsurface pathology cannot be 
evaluated without biopsy. Furthermore, reliance on superficial manifestations can be 
difficult where lesions are visually obscure (e.g. occult), variable in appearance, patchy 
in distribution and/ or occurring in microfoci [2].  Additionally, pathologic mucosal 
changes are often nonspecific due to visual overlaps with other GI diseases [27], [108], 
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[186].  Currently, the only means of diagnostic confirmation and deeper tissue analysis is 
endoscopic based biopsy [108], [174].  
CE demonstrates high sensitivity in the detection of superficial mucosal lesions [187], 
[188].  Despite its lack of biopsy capabilities, CE does have advantages over conventional 
endoscopy in terms of small bowel imaging.  Both ileocolonoscopy and upper endoscopy 
are physically limited to examining only a fraction of the small bowel.  DSBE permits 
small bowel examination, with the added benefit of biopsy and/or treatment.  However, 
full DSBE assessment requires both oral and rectal access.  Unlike the minimally invasive 
nature of CE, DSBE is considered highly invasive, requiring lengthy procedure times, 
and is difficult to perform [189].  The ACG and ECCO recommends that DSBE be 
reserved for specific situations where biopsy or endoscopic intervention is required [5], 
[174]. 
Recommendations by ECCO and the ACG currently relegate CE to a second line or 
adjunct test after ileocolonoscopy and radiological exams [5], [166].  The principle 
reasons for second line status regards the lack of biopsy capability and inability to 
differentiate between bowel pathologies due to visual overlap.  The limited specificity 
and lack of defined diagnostic criteria hinder full adoption of CE into current Crohn’s 
management algorithms [5], [177].   
Despite the relatively high safety profile of CE, there is the potential for capsule retention 
[126].  Although a rare event, <2% of all patients, it is an important risk to consider when 
prescribing for CD patients.  The fibrotic strictures associated with CD increase the risk 
of retention to exceed 8% [127].  A retained capsule represents a form of small bowel 
obstruction and can lead to perforation. Additionally, an ingested capsule is 
Table 2.4.  Advantages and disadvantages of Crohn’s Disease assessment by endoscopy. 
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contraindicated in MRI [128].  Therefore, it is recommended that CE be preceded by 
Patency capsule® administration [111].  The patency capsule is of similar dimensions to 
PillCam™ (11 x 26 mm) and consists of lactose and barium.  The lactose dissolves in the 
GI tract while the barium is radiopaque on X-ray / CT.  The capsule is also fitted with a 
10 x 2 mm Radio-Frequency Identification (RFID) Tag for detection by non-ionising 
means [129]. The capsule is typically taken a few days prior to CE and an intact passage 
of the capsule is indicative of a patent bowel [130].  
  
2.6. Summary and Conclusions  
The human GI tract is responsible for the absorption of nutrients and elimination of waste.  
In order for it to carry out these functions, it is necessary for it to interact with the external 
environment.  To facilitate its fundamental responsibility and maintain sterile internal 
conditions, the GI tract has a highly selective barrier at the environment interface.  
Selectivity is necessary for the ingress/egress of nutrients and waste.  Barrier function is 
necessary to prevent contamination of the sterile internal environment of the human body.  
This is the dual responsibility of the single layer of mucosal epithelial cells lining the 
entire surface area of the GI tract.  Augmenting the single cell layer selective barrier is 
luminal mucus which traps microbes but permits nutrient contact with the epithelium.  
The GI tract also houses a highly sophisticated and organised system that rapidly responds 
to noxious insults to prevent further damage.  It carries a full complement of innate and 
adaptive immune elements responsible for responding to microbial encroachment. 
A barrier breach of the GI immune system results in an acute inflammatory response. 
Acute inflammation initially involves cells of the innate arm, namely neutrophils and 
monocytes. The initial phase of acute inflammation is characterised by a rapid influx and 
accumulation of innate cells.  This is designed to overwhelm and rapidly clear 
immunogenic stimuli.  This initial response is referred to as nonspecific and does not 
retain lasting specific immunological memory.  Adaptive immune cells follow the innate 
cells arm.  It is capable of a highly specific antigen response and maintains immunologic 
memory.  The endpoint of acute inflammation is removal of the noxious stimuli to return 
the affected region to baseline conditions.  Failure to clear immunogenic stimuli results 
in repeated immune activation causing chronic inflammation, a pathologic condition in 
itself. 
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CD is an example of a lifelong chronic inflammatory condition.  The disease is marked 
by features of both acute and chronic inflammation.  Macroscopically, CD is patchy in 
nature with grossly affected areas separated by healthy appearing mucosa resulting in skip 
lesions affecting the entire length of the GI tract.  Histological features include transmural 
inflammation, non-caseating granulomas and focal lesions of organised immune cells.  
Acute, or active, disease is defined by the presence of neutrophils in the LP and crypt 
spaces as either cryptitis or crypt abscesses. 
Imaging of CD for diagnosis and management is by either external or internal means.  
External imaging includes CT, MRI and TABS.  The advantages of these modalities 
include visualisation of the transmural (i.e. cross-sectional) aspect of the bowel and 
provision of information on extraluminal disease manifestations.  Despite these 
advantages, no single modality is superior to another and none has sufficient resolution 
to sensitively detect low grade disease activity.  Furthermore, assessment of active disease 
is hampered by their reliance on nonspecific aspects of inflammation (e.g. oedema).  
Nevertheless, non-ionising means of imaging (e.g. MRI and US) possess an advantage in 
regard to long term repeated scans.  
Internal means for CD assessment relies on endoscopic techniques which include 
ileocolonoscopy, DSBE and CE.  Endoscopy provides a means of directly evaluating the 
mucosa and has proven useful in assessing mucosal healing as a treatment endpoint.  
Nevertheless, reliance on superficial manifestations is limited due to visual overlap with 
other diseases and inability to assess subsurface pathology.  These shortcomings can be 
overcome by tissue biopsy and histopathological analysis.  Both ileocolonoscopy and 
DSBE allow for biopsy but are considered invasive procedures.  CE offers a number of 
advantages over conventional endoscopy.  It is non-invasive, suitable for repeated 
examinations and able to transit the entire GI tract.  These points make CE, on paper, 
ideal for imaging CD.  However, CE is severely disadvantaged by its reliance on mucosal 
manifestations of disease for assessment.  This limits its role and full adoption in the 
diagnosis and management of CD by either ECCO or the ACG.     
The inability to satisfactorily image and fully assess disease activity has created a clinical 
need for a more efficacious means of imaging CD.  An ideal means should be non-
invasive for repeated examinations.  It should be capable of imaging the entire GI tract 
and cross-sectional imaging is paramount to provide deep tissue information.  Image 
resolution must be sufficient to detect disease activity without relying on nonspecific 
signs of inflammation.  Such an imaging modality represents a means of mitigating the 
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need for tissue biopsy and allows for in situ evaluation of subsurface pathology.  Adapting 
high resolution µUS to CE represents a rational concept as it meets the aforementioned 
criteria.  
USCE would provide clinicians a means of evaluating subsurface disease activity along 
the entire length of the GI tract.  Suitable for repeated examinations, USCE would provide 
a way of monitoring disease activity during periods of treatment.  Furthermore, USCE 
has the potential to advance the notion of histological remission by providing high 
resolution subsurface information on disease activity.  Image guidance would better 
inform clinicians as to disease status and response to treatment and permit evidence based 
management decisions. 
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Chapter 3:  Materials and Methods 
 
3. Chapter Introduction 
This chapter describes the materials and methods consistently employed throughout the 
duration of this project.  Procedures related to experiments that deviated from normal 
practice will be addressed in specific sections. 
The Sonopill programme was multidisciplinary project for which I acted as the Clinical 
Research Fellow, Technical Lead (re: diagnosis and therapy) as well a part-time PhD 
student.  As the sole physician on a predominately engineering project I was involved in 
most aspects the programme.  Salient duties included development, planning and 
execution of the in vivo pig experiments, advising on device design and assisting other 
Sonopill related matters.  This meant there was often overlap between my thesis and that 
of other subprojects as there were common goals.    
 
3.1. Materials 
Bowel tissues from mice, pigs and humans were used for the purposes of ex vivo and in 
vivo experiments.  All mouse and human tissue types were used in ex vivo situations and 
pigs were used in both conditions.  
 
3.1.1. Human Tissue 
Human GI tissue was obtained for ex vivo scanning from surgically removed bowel 
samples acquired from areas remote (> 20 cm) from the visually identified tumours by 
the Consultant Pathologist and was presumed healthy.  Five subjects were enrolled 
(Table 3.1).  This study was reviewed and approved by the NHS Tayside Tissue Bank 
Committee (Study Number TR000442).  All patients were informed and consented by the 
Tissue Bank Nurse prior to surgery. 
 
3.1.2. Pigs 
Ex vivo pig experiments utilised abattoir obtained porcine tissue that included samples 
from the oesophagus, small bowel and colon.   Fresh-frozen post-mortem samples were 
purchased from Medical Meat Supplies Ltd (Rochdale, UK).  Tissue samples were  
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 individually vacuum packed, frozen and stored at -4°C. These samples were assumed to 
be healthy tissue as they were originally intended for human consumption. 
In vivo porcine experiments used 20 female Landrace pigs, weight range 40 - 64 kg, and 
age range of 3 – 4 months.  These were obtained from a local breeder/supplier as no 
special requirements were needed.  Pigs were kept in licensed housing (UK Project 
Establishment License 60/4604) in groups of no less than two animals.  The study was 
conducted under Home Office (UK) Procedure Project Licence (PPL): PF5151DAF held 
by Prof Eddie Clutton of the University of Edinburgh (The Royal (Dick) School of 
Veterinary Studies), in accordance with the Animal (Scientific Procedures) Act 1986.  
The project license was modified to include endoscopy experiments.  
 
3.1.3. Mice 
Wild-type C57BL/6 mice were used for all stages of the acute inflammation experiment 
with the exception of stage 2B.  The use C57BL/6 mice was based on documented strain 
susceptibility to dextran sodium sulphate [190]. Two female heterozygous adenomatous 
polyposis coli (ApcMin/+) mice were included in stage 2B.  Ages were 67 - 88 days with a 
median of 74.3 days.  Animals were grouped by sex in each experimental stage (Table 
3.2).  Mice were housed in the University of Dundee Wellcome Building Resource Unit 
(WBRU) and maintained in accordance with UK Home Office guidelines for the care and 
use of laboratory animals under the supervision of Dr Ngaire Dennison, the Named  
 
Table 3.1. Demographics and medical information of patients enrolled on the microultrasound 
characterisation of gastrointestinal tissue study. 
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 Veterinary Surgeon.  The study was conducted under Home Office (UK) Procedure 
Project Licence: P3800598E held by Prof Inke Näthke of the University of Dundee in 
accordance with the Animal (Scientific Procedures) Act 1986. 
3.1.4.  Ultrasound Systems 
Microultrasound (µUS) scanning was performed ex vivo and in vivo with single element 
high frequency transducers and associated equipment.  
 
Single Element Transducers 
Ex vivo scanning was accomplished with two types of single element μUS transducers 
(Table 3.3).  One type of transducer used a piezocomposite element based on lead 
zirconate titanate (PZT), with samples manufactured by Applied Functional Materials Ltd 
(AFM, Birmingham, UK) focused to different depths.   Frequencies ranged from 25 to 50 
MHz.  The second type of transducer was generously provided by Prof Kwok-Ho Lam 
(Hong Kong Polytechnic University, Hong Kong).  This transducer was manufactured 
using lithium niobate (LNO) piezocrystal and operated at a frequency of 62 MHz.  This 
transducer was used in mouse experiment 2B due to its higher frequency.   
Scanning Systems 
The single element transducers were used in conjunction with two bespoke scanning 
systems in two configurations design and built by Drs. C. Démoré, H. Lay and Mr R. 
Poltarjonoks.  The Step Scanner obtained µUS data in a discontinuous transducer step-
stop-scan manner (Figure 3.1A).  The Continuous or ‘Fast’ Scanner maintained a  
 
 
 
 
 
 
 
Table 3.2.  Mouse demographics for acute inflammatory studies; stages 1A, 1B, 2, 3 and 2B. DSS: 
Dextran Sodium Sulphate, WT: Wild Type, ApcMin/+: adenomatous polyposis coli (heterozygous) 
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Table 3.3.  Profiles for the various single element transducers used throughout this project.  Transducers 
were manufactured by Applied Functional Materials Limited (AFM, UK) and Prof Kwok-Ho Lam 
(Hong Kong Polytechnic University).  PZT: Lead Zirconate Titanate piezocomposite, LNO: Lithium 
Niobate 
 
Figure 3.1A-B.  Diagrams of the scanning systems used to collect microultrasound scan data from ex 
vivo tissue samples. Figure 3.1A depicts the Step Scanner.  Figure 3.1B illustrates the Continuous 
Scanner. The former obtains data in a discontinuous manner: the stage motor moves the transducer a 
prescribed distance, stops to scan, and then steps to the next scan point.  This method permits better 
motor accuracy and a high signal to noise ratio (SNR) but requires extended periods of time to acquire 
data due to the slow progression of the transducer.  The Continuous Scanner, by comparison, acquires 
data at a much faster rate.  It permits simultaneous travel and data acquisition without interruption.  
However, there is a concomitant decrease in SNR as result of decreased signal averaging.  Technical 
differences between the two systems are addressed in Appendix A.  Images adapted from Anbarasan et 
al [191]. 
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consistent, programmable, speed, with data being collected during transducer movement 
(Figure 3.1B).  Detailed technical differences between the μUS step and continuous 
scanning systems are outlined in Appendix A.  The arrangement of the μUS step scanner 
system comprises a stepper motor (Sigma Koki Co., Ltd, JP), remote pulser-receiver 
(DPR 500, JSR Ultrasonics, Imaginant Inc., US) and external oscilloscope and computer 
to coordinate and support the μUS scanner.  The frame of the scanning system consists of 
four aluminium pillars mounted between two optical breadboards (Thorlabs Ltd, UK) to 
provide stability during scanning. Within the frame, attached to the optical breadboard, 
are the mobile parts of the scanning system. Two-dimensional (X and Y) motion is 
achieved through the stage (stepper) motors.  The remote pulser was mounted to these via 
an L-bracket, with a goniometer for accurate positioning.  The stage motors were 
connected to an axis stage controller (Sigma Koki Co., JP). The mixed domain 
oscilloscope (Tektronix UK Ltd., UK) recorded the raw electrical echo signal from the 
μUS transducer which was transmitted to a LabVIEW program (National Instruments, 
Austin, US), custom coded to automate the scanning process. 
 
Capsule Based Transducers and Cart 
In vivo pilot studies of USCE required the development and manufacturing of simple 
prototype capsule devices.   Termed ‘Sonocaps’, these tethered devices were designed to 
address a number of basic questions central to the future development of USCE.  
Sonocaps measure 10 mm diameter x 30 mm length (Figure 3.2).  They contain up to four 
single-element spherically focused µUS transducers made with polyvinylidene fluoride 
(PVDF, Precision Acoustics, Dorchester, UK) operating at 30 MHz, with a focal distance 
of 6 mm.  The diameter of each PVDF transducers is 4 mm.  Three transducers were 
placed on one side along the long axis of the Sonocap.  The fourth transducer was situated 
opposite the front end of the capsule, with the tethered end representing the back end. The 
locations of the transducers were chosen to allow a comparison of image quality as a 
function of capsule position along the axis of the capsule. 
All US capsules were manufactured, and safety tested ‘in-house’ by members of the 
Sonopill team which included Drs H. Lay, Y. Qiu and R. McPhillips of the University of 
Glasgow, School of Engineering, and Dr G. Cummins of Heriot-Watt University, School 
of Engineering and Physical Sciences. Safety tests included thermal heating, tether 
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strength, electrical hazards, hermeticity and material toxicity.  Testing was done to ensure 
that capsules did not pose a hazard to animal or operator.  
To facilitate experimental set-up and repeatability, the capsule control and data 
acquisition equipment was located on a mobile cart for use during in vivo testing 
(Figure 3.3).  The capsule was attached to the JSR pulser (JSR Ultrasonics, Imaginant 
Inc., NY, US).  Ultrasound signals were transmitted to each of the four capsule 
transducers via respective micro-coaxial cables (Alpha Wire, NJ, US).  Received echoes 
returned via the same micro-coaxial cable for each transducer.   The electrical power 
supply to the capsule also ran the length of the 3 m tether via two 0.1 mm diameter wires. 
 
 
 
Figure 3.2A-B.  (A) Sonocap microultrasound capsule with 3 of the 4 single element transducers. The 
fourth transducer is situated on the opposite side, distal from the tether (B). Each transducer is 4 mm in 
diameter and manufactured with PVDF (Precision Acoustics, Dorchester, UK). Transducers operate at 
30 MHz, with a focal distance of 6 mm.  Dimensions of the capsule are 30 mm in length x 10 mm in 
diameter.  Afferent and efferent micro-coaxial cables contained in the 3 m tether were connected to 
supporting equipment. 
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Figure 3.3.  Support cart housing control and data acquisition hardware for Sonocap.  Hardware includes 
a LabVIEW-based acquisition graphical user interface (GUI) (1), ultrasound data acquisition and 
monitoring oscilloscope (2), MyRIO (LabVIEW) real-time embedded evaluation board (3), Sonocap 
breakout box for capsule transducer connection to the control and data acquisition hardware (4), 
Ultrasonic pulser/receiver (5) and power supply (6).  Image adapted from Lay et al [192]. 
 
System control was achieved with custom software coded in LabVIEW (National 
Instruments, Austin, US) paired with a myRIO-1900 acquisition device (National 
Instruments, Austin, US) and a commercial ultrasonic pulser/receiver (DPR500, JSR 
Ultrasonics, US), a power supply (EA-PS 2084-03 B, Elektro-Automatik, DE) and 
oscilloscope (MDO3024, Tektronix, US). The proximal end of the tether was attached to 
the myRIO device for real-time data acquisition and control. 
Cart design and assembly was done by Dr H. Lay of the University of Glasgow, School 
of Engineering.  
 
3.2.  Methods 
This section provides a description of the experimental procedures.  
 
3.2.1. Inducing Inflammation 
Inflammation was induced in individual mice with Dextran Sodium Sulphate (DSS).  It 
is frequently employed in IBD studies due its simplicity of administration, cost and 
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reliability [190], [193].  It generally used to induce colitis in mouse models of IBD.  
However, researchers have noted that DSS can cause pan-gastroenteritis, causing 
inflammation from the stomach to colon [194].  Depending on concentration and 
frequency of exposure, DSS can be used to induce acute, chronic or relapsing models of 
intestinal inflammation [193].  A major deviation from human disease is the lack of T and 
B cell involvement in the development of DSS induced inflammation.  Nonetheless, it 
considered applicable to the study of the genesis of intestinal inflammation [190].    First 
described in 1985 by Ohkusa, DSS has been used in multiple studies aimed at determining 
the pathobiology of IBD [195], [196].  The exact mechanism of how DSS induces 
inflammation is not completely understood but it is thought to interrupt GI barrier 
function, exposing immune cells to luminal antigens.  This causes a rapid acute 
inflammatory response [197], [198].  Soluble in water, DSS is a negatively charged 
sulphated polysaccharide with a highly variable molecular weight in the range of 5 - 1400 
KDa.  Animals demonstrate variable responsiveness to DSS molecular weight.  Factors 
involved in response include mouse strain, sex and gut commensals [190], [197], [199].  
Nevertheless, 40 - 50 KDa has been described as the optimum molecular weight for 
inducing bowel inflammation [190], [197].   
Signs of inflammation typically start by Day 3 of ingestion and are maximally manifested 
by Day 7.  Clinical signs include weight loss, diarrhoea and GI bleeding which may be 
occult or overt in nature.  However histological signs may be detected as early as one day 
after introduction of DSS [200].  To induce acute inflammation, 5% DSS (w/v) (MP 
Biochemicals, US) was dissolved in sterile water for oral intake ad libitum for stages 1 - 3 
(Figure 3.4). 
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Figure 3.4.  Experimental plan for inducing inflammation in the gastrointestinal (GI) tract of mice.  Stage 
1A and 1B were pilot studies with the intention to induce visual signs of inflammation to determine 
microultrasound (µUS) feasibility in detecting inflammation.  Stage 2 (34 MHz) and 2B (62 MHz) 
examined the feasibility of µUS to detect the lowest inflammatory grade possible though daily culls and 
scanning of explanted bowel.  Stage 3 was a randomised control trial where animals were assigned to 
control or treatment status by chance. Individual researchers assigned to interpreting data were blinded 
to status.  This stage was designed to determine the lowest grade of inflammation detectable by µUS. 
This study was designated moderate on the severity scale in terms of animal discomfort by the 
University’s Named Veterinary Surgeon (NVS).  This figure was adapted from project licence number 
70/8813 which was reviewed and approved by the UK Home Office.  
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3.2.2.  Mouse: Ex vivo  
Mouse: Acute Inflammation 
Stage 1. 
Stage 1 was a pilot study to determine the ability of µUS to detect overt (i.e. visually 
perceptible) inflammation.  To achieve this, 2 groups of 4 mice segregated by sex were 
used. Stage 1A used an all-male group (N = 4) and stage 1B used an all-female group.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.4.  Study plan outlining the expected adverse events of inducing bowel inflammation with 
Dextran Sodium Sulphate (DSS) 5% (w/v) in drinking water ad libitum.  The parameter and means of 
assessing animal status and resulting action if an adverse event was encountered are also presented.  
Stool grading scheme adapted from Chassaing et al [190]. 
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Each group was sex matched to a DSS negative (DSSneg) control. The two groups were 
to control for sex response differences reported in the literature [197].  Each stage began 
on Day 0 with introduction of 5% (w/v) DSS in drinking water with an intention of dosing 
for 7 days (Day 6) or until a humane endpoint had been reached.  Humane endpoints were 
predefined in cooperation with the Named Veterinary Surgeon (NVS) along with the 
means of assessing tissue for scanning. All mice underwent daily observations which 
included health assessment, weigh-in and faecal examination (Table 3.4).  Daily health 
assessments were done in close collaboration with the WBRU staff.  Trained in 
recognising mouse distress, opinions expressed by a staff member were deemed 
authoritative and prospectively recorded. 
Animals were culled by cervical dislocation and confirmation of death was by 
exsanguination by femoral incision.  Post-mortem dissection of the bowel occurred after 
confirmation of death.  Upon removal, the small bowel, caecum and colon were measured 
for length.  This was followed by preparation of each anatomical section for scanning.  
This involved cleaning and transection along the bowel long axis allowing exposure of 
the mucosa to the transducer.  
A preliminary inspection was done by dissecting microscope (Olympus SZ61, Olympus, 
JP) to ensure the mucosa was facing up and free of debris.  If positive for debris, each 
section was further cleaned in an attempt to achieve total removal of food and faecal 
material to prevent misleading μUS signals.  The tissue was also examined for overall 
status including naturally occurring variations such as Peyer’s Patches.  Finally, the 
sections were assessed for overt signs of inflammation which generally manifested as 
well circumscribed erythematous (i.e. blood red) lesions (Figure 3.5A-B). 
 
Figure 3.5A-B.  (A) Example of an erythematous inflammatory lesion in the caecum after 5 days of 5% 
(w/v) Dextran Sodium Sulphate treatment. (B) Close up of the lesion demonstrating an overt central area 
of erythema bordered by subtler signs of inflammation.      
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Following initial assessment, the samples were transferred to the scanning tray 
(Figure 3.6).  This consisted of a 12.5 cm x 8.5 cm x 2 cm (L x W x H, respectively) 
plastic dish containing an acoustic absorber (Aptflex F28, Precision Acoustics, UK) that 
doubled as a tissue pinning board.  The tissue clamp was pinned to the absorber and the 
tray was filled with 1% (w/v) agar (Formedium, UK) to the level of the struts (i.e. 2 cm 
depth).  The inner space of the clamp measured 30 mm x 15 mm.  During the setting of 
the agar a removable 3.2 cm (L) x 1.5 cm (W) x 0.3 cm (H) Lego (LEGO®, DK) piece 
was used to create a trough between the struts This was done to prevent contact between 
the tissue and agar and provide a distinct µUS tissue signal.  The recess was filled with 
acoustic coupling gel to avoid tissue sag during preparation.  Tissue was secured using a 
Lego constructed tissue scaffold which was designed to secure the tissue and prevent 
excessive curling.  Upon securing the tissue, the scan tray was placed in a slightly larger 
receptacle to contain a combined nutrient - µUS coupling fluid.  Krebs-Henseleit Buffer 
(Sigma-Aldrich, US) titrated to pH 7.4 was used to maintain tissue viability and act as a 
µUS conducting medium for the duration of the scan. 
Prior to scanning, the tissue was optically imaged using a Leica DM750 dissection 
microscope (Leica, Wetzlar, DE).  Care was taken to assure optical images would align 
with µUS images.  This was facilitated by the use of visual markers indicating the 
proximal tissue edge and right side of the Lego clamp (Figure 3.6). 
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Tissue was scanned using a single element transducer and the Continuous Scanner 
described in Sections 3.1.5 and 3.1.6, respectively. 
Scanning tissue samples involved common parameters outlined in Table 3.5.  Transducer 
focal depth, as dictated by the transducers focus point, was set approximately to mid tissue 
depth to account for irregularities in tissue thickness and data acquisition included the 
agar signal.  This resulted in an ultrasound travel time of 6.0 µs on the oscilloscope or a 
focal depth of approximately 4.62 mm.  Gain was set to 40 dB and data averaged 32 times 
per scan point.  Gain and data averaging were arrived at through an iterative process.  The 
two-setting provided suitable imaging results within an acceptable time frame in regards  
 
 
 
 
 
 
 
 
 
Figure 3.6.  Lego mouse scanning tray for ex vivo bowel scanning. The clamp rested upon an acoustic 
absorber to diminish stray echoes and act as a pinning board.  The scaffold and absorber were placed in 
a plastic container which was back-filled with 1% (w/v) agar to the top level of the struts.  During the 
setting of the agar a separate 3.2 cm (L) x 1.5 cm (W) x 0.3 cm (H) Lego piece was used to create trough 
between the struts.  This granted a 3 mm free space between the tissue and agar which was filled with 
acoustic gel.  This kept the tissue free from contact with the agar and granted an independent acoustic 
signal from the two interfaces. Also shown in this image is the typical tissue arrangement for stage 2 
scanning. The green arrows indicating the X and Y direction.  Tissue was arranged from small bowel 
(SB), Caecum (Cae) and Colon (Co) from right to left.  After the tissue was laid across the horizontal 
strut and secured in place using an overlying clamp.  In addition to anchoring the tissue the clamps 
helped mitigate excessive tissue curl that occurred post-mortem.   To ensure proper tissue orientation 
during optical imaging and microultrasound scanning, visual markers were used to indicate the right side 
and proximal tissue portion.  The scanning tray was then placed in a second, slightly larger container 
and filled with nutrient-coupling fluid of choice, e.g. Krebs Henseleit solution. The tissue was submerged 
to appropriate scanning depth.  Stage 3 scanning omitted use of the agar and replaced its lost volume 
with increased fluid.  Co-Colon, Cae-Caecum, SB-Small Bowel 
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to tissue viability. For stages 1A and 1B, total distances in the X and Y directions were 
adjusted for lesion size. 
 
 
 
 
 
 
 
 
 
 
Table 3.5.  Scanning parameters for stages 1A, 1B, 2, 2B and 3 for the mouse inflammatory study.  X 
direction variables (distance and speed) and Y direction variables (total distance and millimetre per step) 
varied until stage 2, 2B and 3 where dimensions were finalised to account for full tissue scanning, time 
per scan and maintaining tissue viability.  The image below illustrates transducer movement in both X 
and Y directions.  This resulted in a microultrasound image composed of several X cross-sectional 
‘slices’ of variable length separated by a number of Y ‘steps’.  Abbreviations: Co-Colon, SB-Small 
Bowel, Cae-Caecum. 
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Following scanning, the tissue was fixed in 4% Paraformaldehyde (PFA) and cold stored 
(4oC) in preparation for histological analysis.  Tissue was stained with Haematoxylin and 
 
  
  
Table 3.6.  Table and illustrative figures of the ordinal grading scheme to assess bowel inflammation.  
Haematoxylin and eosin stained tissue was assessed for histomorphologic alterations which include 
white cell infiltration and mucosal alterations.  Grade 0 demonstrates no signs of inflammatory cell 
infiltration and continuous, intact epithelium.  Grade 1 demonstrates signs of mucosal inflammatory cell 
infiltration (black arrows) without mucosal disruption.  Grade 2 illustrates infiltration at the mucosa and 
submucosa (green arrows) and focal epithelial disruption (blue arrow). Grade 3 is an example of 
transmural inflammation with infiltration at all histologic levels and confluent disruption of the 
epithelium.  Grading scheme was adapted from Erben et al and Elsheikh et al, [194], [201] respectively. 
WBC-White blood cells.  
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Eosin (H&E) and slide mounted per established protocol (Appendix B).  Microscopic 
analysis was accomplished with a Zeiss Axioskop (Zeiss, Wetzlar, DE).  Tissue was 
assessed for changes in morphology, presence of inflammatory cells.  Table 3.6 
summarises the inflammatory grading scheme based on the aforementioned criteria as 
adapted from Erben et al and Elsheikh et al [194], [201], respectively. 
Scan images were analysed qualitatively and compared to both optical images and 
histology slides.  Scan reconstruction is described in Section 3.4.6.  Scan images were 
first assessed for image quality, matched and aligned with their optical images.  Scans 
were then examined for aberrant acoustic signals.  Atypical images would include 
interruptions to normal tissue reconstructions as compared to DSSneg controls.  Images 
were also scrutinised and correlated with the optical appearance of the tissue.  This 
included noting if an aberrant signal was due to the presence of debris.  Images were also 
compared with histology to confirm the presence of inflammation and to correlate scan 
images with histological grading. 
Stage 2  
The aim of Stage 2 was to identify the lowest grade of inflammation detectable by µUS.  
Stage 2 involved 12 mice divided equally between male (N = 6) and female (N = 6) in 
sex separate cages.  Mice were provided 5% DSS (w/v) in the drinking water ad libitum 
for a period of 5 days (Day 0 - Day 4).  Days on DSS were adjusted as males and females 
from stage 1 reached a common humane endpoint on Day 4.  Culling was by cervical 
dislocation and confirmation of death by femoral exsanguination.  Prior to introduction 
of DSS on Day 0, one mouse from each sex was culled and served as a baseline DSSneg 
control.  Subsequently, mice were culled and scanned sequentially every 24 hours.  Cull 
selection of 1 x Male and 1 x Female was done sequentially per unique identifier.  
However, this could be overridden if a humane endpoint was encountered.  All mice 
underwent daily observations which included health assessment, weigh-in and faecal 
examination per Table 3.4. 
The procedure for tissue scanning generally followed the details outlined in stage 1.  
Notable exceptions will be highlighted. Stage 2 inflammation often lacked visual 
evidence (e.g. erythematous lesions) for targeted scanning.  Therefore, a comprehensive 
scan of the samples was required.  This involved loading the tissue clamp with the distal 
ileum, caecum and proximal colon simultaneously as seen in Figure 3.5.  Scan parameters 
were set to 32 mm x 18 mm in the X and Y directions, respectively.  This overlapped with 
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the 30 mm x 15 mm window between struts to include a Lego signal on all 4 sides.  This 
was done to include the Lego as a fiducial marker, ensure full tissue coverage and reduce 
scanner motor errors. The X direction speed was set to 0.2 mm/second and the Y direction 
step size was set to 0.2 mm/step.  This was to ensure complete tissue coverage in a 
reasonable time frame and preserve tissue viability.  Due to limited clamp capacity and 
lengthy scan time (> 4 hours per sample), morning and afternoon scanning were 
necessary.  Morning and afternoon sessions alternated between sexes daily.     
Post scanning, the tissue was processed as described previously.  In order to analyse the 
tissue blindly, histology slides were randomised and coded by the Lab’s Scientific Officer 
[202].  Slides were then batch scanned and digitised by the Tayside Tissue Bank on an 
Aperio Digital Pathology Slide Scanner (Aperio Scanscope XT, Leica, DE) at 40x.  The 
slides were then examined with ImageScope software (Aperio ImageScope, Leica, 
Wetzlar, DE) and QuPath [203].  For each histology sample, an anatomic location was 
assigned, and inflammation was graded based on criteria from Table 3.6.  
Stage 3 
The aim of Stage 3 was to identify the lowest grade of inflammation detectable by µUS 
in a randomised control trial (RCT).  Mice were randomly assigned to either a control or 
treatment group.  The treatment group was further assigned to length of treatment 
randomly.  This was done by the Lab’s Scientific Officer using a list randomiser [204].  
Stage 3 involved 16 mice in total (N = 16).  Treated mice were provided with 5% DSS 
(w/v) in the drinking water ad libitum.  All mice underwent daily observations which 
included health assessment, weigh-in and faecal examination per Table 3.4.  Culling was 
by cervical dislocation and confirmation of death by femoral exsanguination.  
The procedures for tissue scanning followed Stage 2 with two notable exceptions.  Bowel 
prep was improved by gently brushing the tissue with a paint brush.  This helped remove 
adherent debris from the tissue mucosa.  Secondly, the scanning tray arrangement did not 
use agar and substituted the lost agar volume with additional Krebs-Henseleit Buffer.  
Complete scanning of the samples involved loading the tissue clamp with the distal ileum, 
caecum and proximal colon simultaneously similarly arranged as in Figure 3.6.  Scan 
parameters were set to 32 mm x 18 mm.  The X direction (32 mm) speed was set to 
0.2 mm/second and the Y direction (18 mm) step size was set to 0.2 mm/step.  Scanning 
sessions were in both the morning and afternoon.     
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Post scanning, the tissue was processed as described previously.  One notable exception 
was to keep the tissue in the Lego scaffold for a period of 24 hours during fixation.  This 
was to prevent tissue curl that occurred during the fixation process.  In order to analyse 
the tissue blindly, the tissue was coded by the Lab’s Scientific Officer [202].  Slides were 
then batch scanned and digitised by the TMA and Image Analysis Unit at the University 
of Glasgow on a Hamamatsu NanoZoomer NDP (Hamamatsu, JP) at 40x.  The slides 
were then examined on QuPath.  Each tissue scan was compared to the dissection 
microscope image simultaneously to rule out the presence of debris as a cause of aberrant 
signals.  Scans were then examined for evidence of inflammation (i.e. aberrant signals) 
and results were correlated with histology to confirm the presence of inflammation.  
 
Stage 2B 
The aim of Stage 2B was to identify the lowest grade of inflammation detectable by µUS 
at 62 MHz.  Stage 2B involved 7 mice (4 female, 3 male).  Mice were provided 5% DSS 
(w/v) in the drinking water ad libitum for a period of 5 days (i.e. Day 0-Day 4).  Culling 
was by cervical dislocation and confirmation of death by femoral exsanguination.  Prior 
to introduction of DSS on Day 0, one female mouse was culled and served as a baseline 
DSSneg control.  Culls began on Day 2 after 48 hours of DSS exposure.  All mice 
underwent daily observations which included health assessment, weigh-in and faecal 
examination per Table 3.4. 
The procedure for tissue scanning generally followed the details outlined in Stage 3.  Post 
scanning, the tissue was processed as described previously.  Slides were then batch 
scanned and digitised by the TMA and Image Analysis Unit at the University of Glasgow 
on a Hamamatsu NanoZoomer NDP (Hamamatsu, JP) at 40x.  The slides were then 
examined on QuPath.  
 
3.2.3. Human Ex vivo  
The aim of scanning ex vivo human tissue was to apply various µUS frequencies to 
determine their ability to resolve the histological layers of the GI tract.  This pilot study 
was reviewed and approved by the Tayside Tissue Bank Committee and conducted in 
collaboration with NHS Tayside and Tayside Biorepository.   
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Surgical (i.e. bowel resection) cases were identified by the Biorepository Nurse, Sally 
Chalmers.  Anatomical inclusion criteria included ileum, ileocaecal valve, ascending 
colon and intestine not otherwise specified.  This was later amended to include transverse 
and descending colon in order to provide appropriate numbers to complete the project.  
Pathology criteria included inflammatory and neoplastic diseases.  All patients were 
informed and consented prior to surgery by the Biorepository Nurse.  
Immediately following surgical excision, tissue was delivered to the Consultant 
Pathologist for processing. This involved transecting the bowel and inspection by the 
Consultant Pathologist.  After visually identifying the location of the tumour, an area of 
bowel, approximately 20 cm from the tumour, was chosen and sectioned out for µUS 
scanning.  The sectioned-out samples were approximately 3 cm x 3 cm in size.  As the 
samples were remote from the site of pathology, they were presumed healthy. 
The tissue was then moved to a µUS scanning chamber comprising an acoustic absorber 
covered with 2% agar (w/w) (Fisher Scientific, UK) in a 135 x 85 x 55 mm3 plastic tub 
containing a Lego Scaffold (LEGO®, Billund, DK) to raise the tissue off the agar 
(Figure 3.8).  The agar between the scaffold platforms was covered with 1 - 2 mm of 
ultrasound coupling gel (Diagnostic Sonar Ltd, Livingston, UK) to ensure that the tissue 
was lifted off the agar to produce an isolated acoustic signal. The samples were pinned 
using 4 x 25G Microlances (Becton Dickinson, UK) and submerged in dPBS to a level 
allowing for sufficient µUS transducer immersion.  Ultrasound focal depth was 
approximately at the level of the submucosa.  The focus was set below the surface to 
account for variations in the height of the tissue and resulted in a transducer to tissue 
distance of approximately 4.0 mm. 
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Microultrasound scanning was performed using a selection of single element transducers 
operating at frequencies in the range 25 - 50 MHz (Table 3.3).  
Analysis consisted primarily of reviewing the resultant µUS data and comparing results 
to human colon histology.  Results were specifically analysed for discerning and display 
the cardinal histologic layers (i.e. mucosa, submucosa, muscularis propria and serosa).  
 
3.2.4. Pig In Vivo  
Pigs were used to test the feasibility of our prototype USCE to image the GI tract.  
Experiments were designed to address three fundamental concerns regarding the in vivo 
performance of USCE: whether intimate contact occurred between the US transducer and 
the gut mucosa, the quality of the acoustic signal (i.e. to discern cardinal bowel layers), 
and the optimal acoustic position of the transducer on the capsule (e.g. mid or end 
capsule). 
All pig trials were conducted at Dryden Farm, a constituent of the Roslin Institute, 
University of Edinburgh, and attended by certified veterinary staff.  Pigs were kept in 
licensed housing (UK Project Establishment License 60/4604) in groups of no less than 
two animals.  Environmental variables were maintained within the limits detailed by the 
 
Figure 3.7.  Lego scaffold used to support ex vivo tissue, both human and pig, during scanning.  The 
tissue supports were adjustable in width and had 20 pin holes to accommodate tissue of varied sizes.  
The scaffold rested upon an acoustic absorber which served to diminish stray echoes and act as a pinning 
board.  The scaffold and absorber were placed in a plastic container which was back-filled with 1% (w/v) 
agar to the bottom level of the tissue supports.  This granted 1 - 3 mm free space between the tissue and 
agar which was filled with acoustic gel, keeping the tissue free from contact with the agar and granting 
independent acoustic tissue signals.  Coupling fluid of choice, e.g. PBS, could then be used to submerge 
the tissue to an appropriate scanning depth. 
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Project Establishment License (PEL). This study was approved by the Animal Welfare 
and Ethical Review Board of the Roslin Institute, Roslin, Midlothian, EH25 9RG, and 
was carried out under Home Office (UK) License PPL PF5151DAF.  All in vivo capsule 
manipulation was performed by individuals hold a Home Office issued Personal Licence 
(PIL).  Obtaining a licence required attending the ScotPIL training course at the 
University of Edinburgh.  Course work and training (animal familiarity/handling) was on 
both small animal (e.g. rodent) and large (e.g. pig and cow).  A passing mark permitted 
application for a Home Office issued alpha-numeric licence.  In addition, operators 
required competency assessment by the University of Edinburgh NVS.  Capsule 
manipulation and endoscopy were performed by Dr R. McPhillips (PIL I9999073A) and 
the author, Dr B.F. Cox (PIL IA8090490).    
Over the course of seven separate experiments, twelve Landrace pigs (Sus scrofa 
domesticus) were non-recovery anaesthetized and prepared for in vivo USCE testing.  All 
pigs were female, approximately 6 months in age and weighed between 50-60 kg.  Per 
Home Office directive, all animals were euthanized upon completion of the experiment.    
Prior to unit arrival at Dryden Farm pigs were provided full rations and housed on straw.   
Upon arrival they were housed in a pen with rubber matting replacing the straw.  The 
removal of straw was necessary as the consumption of high fibre straw and associated 
debris (e.g. pebbles) proved difficult to flush out of the small bowel.  This interfered with 
conventional endoscopic and USCE imaging.  Cleanliness of pigs on the rubber matting 
was initially poor, but much improved by increasing the floor space available and raising 
the rubber matted area so the pigs could designate separate latrine and sleeping areas more 
effectively.  Heat lamps and environmental enrichment items (e.g. chew toys) were 
provided for warmth and to maintain healthy behaviour, respectively [205].  
Originally, pigs were provided full rations and housed in straw bedded pens.  However, 
it was apparent that pig consumption of the high fibre straw and associated material (e.g. 
pebbles) compromised bowel cleanliness.  Furthermore, the indigestible fibre proved 
difficult to flush from the lumen.  This may have led to bowel injury through over 
manipulation as evidenced by post-mortem examination.  Therefore, a modified diet was 
necessary to improve bowel preparation.  This entailed providing a low residue (i.e. low 
fibre) based nutritional supplement. Glutalyte® (Norbrook®, Newry, UK) is a 
commercially available product consisting principally of electrolytes and carbohydrates.  
It is intended for calves during periods of digestive disturbance. It was prepared according 
to manufacturer’s recommendations of one sachet dissolved in 2 L of warm water.  
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Glutalyte was introduced in small volumes of 2 L between two pigs every 12 hours.  This 
was done upon arrival at Dryden Farm to acclimate the pigs to the supplement.  Generally, 
the supplement was found to be palatable by the pigs.  Commercial pig feed (Rearer 
Pellets, ABN, UK) was provided until 36 hours prior to induction of anaesthesia.  The 
pigs were then offered Glutalyte ad libitum equating to 2 L per pig every 12 hours until 
they were anaesthetised.  Water was always available at 2 L per pigs every 12 hours ad 
libitum. During this period, baseline body weight was maintained, and blood glucose was 
found to be within normal limits.  
Pigs were arranged in either a lateral (e.g. right side) or supine (i.e. on their back) position 
on the surgical table (Figure 3.9A).  Position depended on abdominal stoma placement 
(Figure 3.9C and 3.9D).  For oesophageal access, pigs were placed in a supine position.  
To preserve body temperature but maintain stoma access, the pigs were provided with a 
Bair Hugger warming blanket (3M™, US).  The trachea was intubated, and anaesthesia 
was induced with isoflurane (IsoFlo, Zoetis, UK) vaporized in oxygen and nitrous oxide 
administered via a breathing system and facemask. Anaesthesia was maintained with 
isoflurane. Ringer’s lactate solution (Aqupharm No 11, Animalcare, UK) was 
administered at 10 ml kg-1 hr-1 throughout each study to maintain fluid and electrolyte 
levels.  The anesthetized pigs’ lungs were mechanically ventilated to maintain 
normocapnia (i.e. normal blood CO2 levels). Vital signs were monitored throughout the 
experiment by a licenced veterinary anaesthetist.  When the experiments were complete, 
the animals were euthanized using pentobarbital. 
Oesophageal Experiments 
For the oesophageal experiments, a modified wide-diameter endotracheal (ET) tube was 
placed directly in the oesophagus.  This was done to bypass the obstacle created by the 
anaesthetic tubing (Figure 3.9B).  To assist with transducer-tissue coupling, a saline drip 
(≈ 1 - 2 drips/s) was used.  The capsule was inserted orally, down the length of the ET 
tube into the proximal oesophagus.  Capsule imaging of the oesophagus consisted of both 
static and dynamic scans.  Static imaging was done in 3x positions which included 
proximal, middle and distal (i.e. gastroesophageal junction (GOJ)).  Dynamic scans 
involved placing the capsule at the GOJ and slowly drawing it towards the mouth at rate 
of approximately 1 cm/s.  
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Small Bowel Experiments 
For small bowel experiments, direct access to the small bowel was gained through the 
surgical creation of an enterocutaneous stoma, bypassing the upper GI tract (oesophagus, 
stomach and duodenum).  This avoided the challenges of having to navigate the capsule 
into the small bowel.  Furthermore, it mitigated the need for longer capsule tethers.  Stoma 
creation began with a 10 cm incision in the lateral side or midline of the abdomen by a 
qualified veterinary surgeon.  The jejunum was identified and a 10 cm incision along the 
long axis of the bowel was created, allowing access to the lumen.  The bowel was then 
suture secured to the subcutaneous layer of the dermis (Figure 3.9C).  The long axis bowel 
incision opened the lumen to both antegrade (i.e. stoma to distal bowel) and retrograde 
(i.e. stoma to proximal bowel) capsule manipulation (Figure 3.9D).  Following stoma 
  
 
 
Figure 3.8A-D.  Operating room set-up for pig trials. (A) Equipment setup including anaesthetic and 
monitoring devices (upper right), standard ultrasound machine (centre left) and experimental trolley 
(lower right). Test subject with warming blanket (centre). (B) Modified endotracheal tube (ET) allowing 
direct access to the oesophagus. (C) An artificial enterocutaneous small bowel stoma located on the 
lateral side of the abdomen with inserted capsule (tether visible). Also visible is saline drip used to assist 
with ultrasound coupling and prevent wound dehydration. (D) A midline small bowel stoma with a 
capsule and thermometer inserted distally and proximally, respectively (tethers visible).  
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creation, the bowel was inspected for the presence of food residue. The bowel was then 
flushed with 37°C normal saline solution (0.9% NaCl g/L) if necessary.  
Capsule examination of the small bowel involved both static and dynamic modes of 
imaging.  In each case, an attempt was made to insert the capsule in the antegrade (i.e. 
proximal to distal) direction; however, the lack of reliable external guidance meant that 
this could not be guaranteed.  Static imaging consisted of inserting the capsule in a 
proscribed distance (≈ 60 cm) and stationary transmural µUS data was collected for all 
four transducers.  The process was repeated with capsule movement ≈10 cm retrograde 
until the capsule exited the stoma.  Although static in terms of operator manipulation, 
movement due to peristalsis could not be ruled out.  Dynamic scans involved inserting 
the capsule ≈ 60 cm and pulling the capsule back in 12 cm increments over a 30 second 
duration while µUS signals were recorded.  As with the oesophageal studies, a saline drip 
(≈ 1 - 2 drips/s) was used to assist with µUS coupling and prevent dehydration of the 
stoma exposed bowel [206][207]. 
Scan analysis focused on addressing the three fundamental concerns regarding in vivo 
performance of USCE.  Images were analysed for adequate transducer-mucosal coupling, 
image quality, identifying bowel tissue and cardinal layers.  Results from in vivo 
experiments were also compared to ex vivo capsule results which provided isolated tissue 
images of pig bowel [208].  Optimal placement of the transducer on the capsule was also 
reviewed.  
 
3.2.5. Microultrasound Image Reconstruction 
Brightness (B) scan images were reconstructed from in vivo and ex vivo A-scan µUS data. 
This was achieved using a bespoke MATLAB (Mathworks, Natick, US) script designed 
to work in conjunction with the single-element scanning systems to streamline data 
acquisition, simplify data reconstruction and allow custom B-scan image presentation. 
Two-dimensional B-scans were created using averaged radiofrequency (RF) echo data 
with relative echo strength and colour mapped. 
MATLAB programming was done by Drs S. Sharma, V. Bentivegna, H. Lay, C. Lemke 
and A. Chandra.  
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Chapter 4. Human Tissue Experiments 
 
4. Chapter Introduction 
This chapter describes microultrasound (µUS) scanning of surgically explanted human 
colonic tissue. The purpose of this pilot study was twofold. One aim was to tentatively 
identify a suitable frequency for inclusion into USCE. The other aim was to examine the 
relationship between acoustic tissue layers and histological layers as illustrated in chapter 
1, figure 1.6A-C (p. 13). To achieve both of these aims, freshly acquired human colonic 
tissue was scanned at various µUS frequencies in three different orientations with respect 
to the µUS transducer (Figure 4.1).  Scanning tissue in various orientations with high 
frequency µUS transducers has the potential to further elucidate the relationship between 
histology and the acoustic layers.  This maybe particularly true at 90° as signals are 
generated exclusively from layer components.  As introduced in Chapter 1, there is a 
debate as to the origin of the ultrasonic layers and whether they directly equate with 
histologic layers.  Kimmey et al hypothesised that echoes arose from both layer interfaces 
and the components of each layer [56].   
 
4.1. Optical Tissue Examination 
Tissue from each patient or ‘case’ was brought directly from the surgical theatre to 
Pathology for inspection and processing. The tissue was examined at both the 
macroscopic (gross) and microscopic (histologic) levels. This was done to enable a 
comparison between the scan results and more conventional methods of tissue 
examination and to assist with interpreting ultrasound (US) results.  
Figure 4.1A-C. Illustration of tissue orientation in relation to the transducers. (A) Standard scan where 
the mucosa faced the transducer. This orientation provided a mucosa to serosa cross-sectional image. 
(B) The tissue was rotated 90° so that each individual tissue layer faced the transducer. (C) The tissue 
was rotated 180° so that the serosa faced the transducer. This orientation provided a reversed cross-
sectional image. 
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4.1.1. Macroscopic Examination 
A total of five cases were included in this study and tissue was collected exclusively from 
the colon.  Neoplastic disease was the reason for all five procedures.  The site of the 
tumour was identified by the consultant pathologist (Figure 4.2).  A 3x3 cm healthy 
section roughly 20 cm from the tumour was removed for scanning.  Samples were 
inspected and photographed prior to US scanning (Figure 4.3). 
Figure 4.2A-C.  (A) Ascending colon from Case 2. The pathologist has indicated the location of the 
tumour with forceps from the serosal side. (B) Ascending colon from Case 3. The subserosal taenia coli 
(arrow), a ribbon of smooth muscle that runs the length of the colon, can be seen. Haustra or sacculations 
were visible (arrowhead), which are created by contraction of the taenia coli. Both Cases 2 and 3 were 
imbued with numerous fatty appendages termed epiploic appendices (chevron). (C) In this image, the 
pathologist has shown the ileocaecal valve from the mucosal side of the caecum. 
Figure 4.3A-E.  Colon sections from Cases 1-4. Sections were taken from an area approximately 20 cm 
from the tumour. At this distance, the tissue was presumed healthy. (A) Case 1 image of the mucosa in 
the tissue scaffold. The mucosa appeared smooth, without visible defects. (B) Case 2 had multiple 
mucosal surface irregularities which included pitting and folds. (C) Case 3 also showed multiple surface 
irregularities in the form of mucosal folding. (D) Case 2 transmural image from the mucosa to serosa. 
The tissue appeared well organised without obvious defects. (E) Case 4 transmural image. Although a 
large defect is noted on the right of the sample, the scanned area (arrowhead) did not appear grossly 
deformed. 
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4.1.2. Histologic Examination 
Histologic examination of the tissue was performed on Cases 1, 2 and 4 (Figure 4.4). 
Slides were produced by the Pathology Department and originated from locations in close 
proximity to the tumour but were from outside the tumour margins and considered disease 
free. As the slides were not from the scanned tissue, histology was used only as a rough 
indicator of the colon architecture and morphology. 
 
Figure 4.4A-C.  Haematoxylin and eosin histology slides from Cases 1, 2 and 4. Tissue for histology 
originated from locations in close proximity to the tumour and was, therefore, distant from the ultrasound 
(US) scanned area. Nevertheless, the figure slides were from outside the tumour margin, considered 
disease free and were used only to approximate colon status. (A) Case 1 appeared morphologically 
normal and architecturally well organised compared to text references [70]. (B) Case 2 appeared 
architecturally normal, however, the submucosa appeared thickened and the muscularis propria thinned. 
(C) Case 4 appeared architecturally normal, however, the submucosa appeared thinned and the division 
between the inner and outer muscularis propria muscles was pronounced. M (mucosa), *(muscularis 
mucosa), SM (submucosa), MP(I) (inner muscularis propria), < > (division between muscle layers), 
MP(O) (outer muscularis propria), S (serosa). 
4.2. Microultrasound Results 
Microultrasound results were grouped according to tissue orientation.  Cases 1-3 were 
scanned with the mucosa facing the transducer providing a mucosa to serosa cross-
sectional image.  Case 4 tissue was rotated 90° so each histological layer was individually 
scanned.  For Case 5, the tissue was rotated 180° so the transducer faced the serosa which 
provided a serosa to mucosa cross-sectional image.  All images are presented in ‘Jet’ 
colour format which showed hyperechoic, hypoechoic and anechoic signals as red-
orange, yellow-light blue and dark blue, respectively.  Results are summarised in Table 
4.1. 
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Table 4.1.  Summary of human tissue scan results at various microultrasound (µUS) frequencies.  Greyed 
out blocks indicate that scan was not done at that particular frequency.  This was often due to lack of 
transducer availability, transducer failure or time constraints.   
4.2.1. Cases 1-3 
Case 1 
Tissue from Case 1 was scanned at 25, 34 and 50 MHz (Figure 4.5A-C).  Case 1 at 25 
MHz showed five distinct µUS layers between the surface (i.e. mucosa) and the serosa.  
The superficial mucosal layer was hyperechoic, which was followed by a deeper 
hypoechoic layer.  The signal became uniformly hyperechoic and formed the third layer.  
The signal then changed and formed a predominately anechoic layer with hypoechoic 
elements.  The final layer was a mixed hyper/echoic layer which corresponded to the 
serosa and mesenteric fat.  The same tissue at 34 MHz revealed seven distinct ultrasonic 
layers from the mucosa to serosa.  The first layer was a thin hypoechoic band and was 
followed by a thin anechoic stripe. The third layer was mixed hyper/hypoechoic.  The 
fourth layer was a mixed hypo/anechoic layer.  The final layer was hypoechoic, 
containing scattered hyperechoic elements.  Tissue at 50 MHz showed seven distinct 
layers.  The first and second layers were thin hypoechoic and anechoic stripes, 
respectively.  The third layer was mixed hyper/hypoechoic and the fourth layer was 
anechoic with hypoechoic elements.  The next layer was predominately hyperechoic with 
hypoechoic regions and was followed by a sixth uniformly anechoic layer.  The final layer 
was a mixture of all three signal types.  The decreased acoustic layers from nine at 34 
MHz indicated signal attenuation.  This was illustrated by the increased contribution of 
anechoic signals at deep layers compared to at 25 and 34 MHz. 
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Case 2 
Tissue from Case 2 was scanned at 25 and 34 MHz (Figure 4.6A-B).  The 25 MHz scan 
revealed three layers from mucosa to serosa.  The first layer was hyperechoic and the 
second was hypoechoic.  The final layer was predominately hyperechoic with hypoechoic 
elements.  The same tissue at 34 MHz showed four layers from mucosa to serosa.  The 
first layer was a hyper/hypoechoic layer.  The second layer was predominately anechoic 
with scattered hypoechoic regions.  The third layer was mixed hyper/hypoechoic and 
transitioned into a hypoechoic fourth and final layer. 
 
Case 3 
Tissue from Case 3 was scanned at 25 and 37 MHz (Figure 4.7A-B).  Images from both 
frequencies failed to depict any distinct tissue layers.  The only notable difference 
between 25 MHz and 37 MHz is the increased signal intensity at the tissue surface at 37 
MHz. 
 
4.2.2. Case 4 
The tissue for Case 4 was orientated so that all layers faced the transducer and could be 
scanned individually (Figure 4.8A-B).  In this arrangement, each histologic layer 
generated its own acoustic signal which was generated by the tissue composition alone.  
The tissue was scanned at 25 and 37 MHz.  The scan began at the mucosa (X=0 mm) and 
terminated at the serosa (X=15 mm). 
 
At 25 MHz, five distinct layers were detected.  The first layer was predominately 
hyperechoic with scattered hypoechoic regions.  The second layer was hypoechoic and 
became hyperechoic to form the third layer.  The fourth layer was hypoechoic and 
transitioned to a mixed hyper/hypoechoic final fifth layer. 
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Figure 6.5A-C. Results from Case 1 scanned at 25, 34 and 50 MHz (A, B, and C, respectively).  
Ultrasonic layers were depicted as hyperechoic (e.g. red-orange), hypoechoic (yellow-light blue) and 
anechoic (e.g. dark blue).  Results demonstrated both enhanced resolution as well as decreased tissue 
penetration with increasing frequency.  At the superficial level, 25 MHz showed 2 distinct layers (1A 
and 1B) whilst 34 and 50 MHz showed 4 distinct layers (1A-1D).  All 3 frequencies portrayed a 
hyperechoic second layer and a predominately anechoic third layer.  Scans at 25 and 34 MHz included 
a mixed anechoic/hypoechoic third layer (3).  Layer 3 at 50 MHz scan was predominately anechoic.  
Signal is also diminished from the fourth layer with 50 MHz as compared to 25 and 34 MHz             
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Figure 4.6A-B.  Tissue from Case 2 was scanned at 25 and 34 MHz (A and B, respectively).  Ultrasonic 
layers were depicted as hyperechoic (e.g. red-orange), hypoechoic (e.g. yellow-light blue) and anechoic 
(e.g. dark blue).  The results showed enhanced resolution with increasing frequency.  The 25 MHz scan 
demonstrated three layers with a first hyperechoic layer and second hypoechoic layer.  The final layer 
was predominately hyperechoic with hypoechoic elements.  At 34 MHz, four layers were detected.  The 
first layer was a mixed hyper/hypoechoic layer.  The second layer was predominately anechoic with 
scattered hypoechoic regions.  The third layer was mixed hyper/hypoechoic and transitioned into a 
hypoechoic fourth and final layer. 
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Figure 4.7A-B.  Tissue from Case 3 was scanned at 25 and 37 MHz (A and B, respectively).  Ultrasonic 
layers were depicted as hyperechoic (e.g. red-orange), hypoechoic (e.g. yellow-light blue) and anechoic 
(e.g. dark blue).  At 25 MHz, the image was a mix of all three signal types, but no discernible layers 
were detected.  At 37 MHz, signals were also a mix of all three signal types. 
 
At 37 MHz, nine distinct ultrasonic layers were detected.  The first layer was mixed 
hyper/hypoechoic, which was followed by a hypoechoic layer.  The next layer was mixed 
hyper/hypoechoic and the fourth layer was hypoechoic.  The fifth layer was hyperechoic.  
The sixth, seventh and eighth layers were hypoechoic, hyperechoic and hypoechoic, 
respectively.  The final ninth layer was hyper/hypoechoic.        
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Fig 4.8A-B.  Case 4 at 25 MHz and 37 MHz (A and B, respectively).  The tissue was oriented so that 
each histological layer was scanned individually.  Tissue was depicted by hyperechoic (orange-red) and 
hypoechoic (yellow-light blue) signals.  At 25 MHz, five layers were revealed.  The first layer was 
predominately hyperechoic with scattered hypoechoic regions.  The second layer was hypoechoic and 
became hyperechoic to form the third layer.  The fourth layer was hypoechoic and transitioned into a 
mixed hyper/hypoechoic final fifth layer.  At 37 MHz, there were nine ultrasonic layers.  The first layer 
encountered was mixed hyper/hypoechoic and was followed by a hypoechoic layer (1A-1B).  The next 
layer was mixed hyper/hypoechoic and the fourth layer was hypoechoic (1C-1D).  The fifth layer (2) 
was hyperechoic.  The sixth, seventh and eighth layers were hypoechoic, hyperechoic and hypoechoic, 
respectively (3A-3C).  The final layer was hyper/hypoechoic (4).    
    
4.2.3. Case 5 
Tissue from Case 5 was arranged with the serosa facing the transducer to generate a serosa 
to mucosa cross-sectional image (Figure 4.9).  The tissue was scanned at 25 and 37 MHz.  
Image reconstruction and analysis was hampered by the poor signal-to-noise ratio (SNR).  
The 25 MHz scan has not been included.  The 37 MHz scan showed mixed echoic signal 
types.  There were five distinct signals on either side of a mixed hyperechoic/hypoechoic 
cluster located mid-tissue.  The serosa was mixed hyperechoic/hypoechoic.  The second 
and fourth layers were predominately anechoic, separated by a thin hypoechoic stripe.  
The final fifth signal, which corresponded to the mucosa, appeared as a patchy mix of all 
three signal types. 
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Figure 4.9.  Tissue from Case 5 was scanned at 37 MHz and the serosa faced the transducer.  Ultrasonic 
layers were depicted with hyperechoic (e.g. red-orange), hypoechoic (e.g. yellow-light blue) and 
anechoic (e.g. dark blue) signals, although the signal-to-noise ratio (SNR) was compromised.  There 
were five distinct layers on either side of the mixed hyperechoic/hypoechoic cluster located at 8-11 mm 
along the horizontal axis.  The superficial layer, which equated to the serosa, was mixed 
hyperechoic/hypoechoic.  The second and fourth layers were predominately anechoic and were separated 
by a thin hypoechoic stripe.  The final fifth layer, which corresponded to the mucosa, appeared as a 
patchy mix of all three signal types. 
4.3. Discussion 
Scanning of human tissue with high frequency single element transducers demonstrated 
that µUS can image colonic tissue with greater detail than standard 7-12 MHz 
frequencies.  As expected, higher frequencies revealed not just the primary histologic 
layers, but also a number of sublayers.  This was evident at the superficial level, as the 
number of distinct layers increased up to four separate layers versus the single layer seen 
at standard frequencies.  Additionally, the results demonstrated a decrease in tissue 
penetration at deeper layers, as seen in Case 1 results. 
One aim of this pilot study was to tentatively identify an optimal frequency for inclusion 
into Sonopill.  My results indicated that ≈35 MHz is a potentially acceptable frequency; 
34 and 37 MHz provided a high degree of superficial tissue detail.  Furthermore, both 
frequencies demonstrated sufficient transmural penetration.  Similar conclusions 
regarding 35 MHz were reached in an independent project on the µUS surveillance of 
Barrett’s oesophagus using explanted pig oesophagus [209].  Confirming these 
preliminary conclusions will require a functional USCE operating at a similar centre 
frequency tested in vivo.  
The second aim was to examine the relationship between high frequency µUS, detailed 
by acoustic tissue layers and histology.  Histologically, the tissue from Case 1 appeared 
to be well organised and morphologically unremarkable.  This was consistent with the 
µUS scan of the tissue showing distinct and well-demarcated acoustic layers.  In fact, the 
34 MHz scan closely resembled the acoustic-histologic relationship proposed by 
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Ødegaard et al. and introduced in Chapter 1 [36].  Nevertheless, none of the frequencies 
used depicted the myenteric plexus dividing the inner and outer muscles of the muscularis 
propria (MP).  Histology from Case 2 showed a thickened submucosa (SM) and thinned 
MP.  These morphological changes may have been detected by µUS.  The scan showed a 
prominent hyperechoic band, which potentially corresponded to the thickened SM. 
Furthermore, the deep anechoic-hyperechoic bands normally associated with the MP 
were not detected. The results from Case 1 indicated that µUS was capable of replicating 
normal histology. The results from Case 2 indicated that µUS was capable of depicting 
pathophysiologic changes associated with age and/or disease [210]–[212]. 
Regardless, the standard orientation µUS scans failed to resolve the exact relationship 
between US layers and histology.  A major contribution to this shortcoming was the lack 
of histology that corresponded more directly with scanned areas.  While the slides 
provided an approximate picture of the state of the tissue.  However, this resulted to 
considerable speculation when comparing scan results to histology.  Any future studies 
will require sampling, both scanning and histology, from the same location.   
By rearranging the tissue by 90° and 180°, the effects of tissue composition and layer 
interface on image generation could be further examined.  Scans performed in the 90° 
orientation produced variable strength echoes that appeared to be arranged in distinct 
layers (Figure 4.8).  This arrangement permitted each histological layer to be scanned 
separately.  The signals generated were based predominately on the internal composition 
of each layer.  The 90° scan at 37 MHz produced a multi-layered image that 
approximately matched Ødegaard’s figure in terms of layer numbers and distribution (see 
Figure 1.6A-C, Chapter 1, page 13).  A comparison of Case 1 and Case 4 revealed a 
similar echo pattern based on layer composition (Table 4.2).  Case 4 results could be 
improved with better tissue support (e.g. suspending the sample) to prevent artificial 
elongation and weight-induced buckling.  Additionally, placing the transducer closer to 
the tissue would better isolate the signal generated by each layer [56].  Tissue scanned in 
this orientation relationship offers an alternate means of looking at the ultrasound-
histology relationship.   
Tissue scanned at 180°, where the tissue interfaces were reversed, was intended to 
determine if this would produce a mirror image of a standard orientation scan.  As the 
µUS wave travel was simply reversed, the potential to produce a mirror image seemed 
logical.  However, reversing the order of tissue interfaces could potentially alter image 
generation.  For instance, the smooth serosa would reflect µUS differently than the  
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irregular mucosal surface.  It would be reasonable to expect a more specular reflection 
from the flatter serosa [56].  Unfortunately, the single result and poor SNR was 
insufficient to fully demonstrate the effect of reversing the tissue.  Nevertheless, this 
method also represents a practical means of examining the ultrasound-histology 
relationship.  This would be especially informative if done in conjunction with scanning 
of the same sample in both standard and reversed orientation.    
 
4.4. Summary and Conclusion 
In this chapter, I have described the results obtained from µUS scans on freshly acquired 
human colonic tissue scanned at various frequencies.  This was done to identify a suitable 
frequency for USCE and further explore the ultrasound-histology relationship.  Although 
constrained by a small sample size, particularly for the reoriented cases, the results of this 
pilot study met some of the stated aims.  The results have indicated that a centre frequency 
of 35 MHz is a potentially suitable frequency for USCE inclusion.  At ≈35 MHz, 
enhanced tissue detail and full transmural penetration were observed.  Scan results were 
also compared to available histology.  Case 1 scans replicated observed histological 
morphology and architecture.  Tissue was also scanned in different orientations.  Tissue 
scanned at 90° revealed an image based on layer composition alone.  The intention of 
scanning at 180° was to show the effect of rearranging tissue interfaces on image 
generation.   
 
Table 4.2.  Comparison of acoustic layers signal strength in standard (mucosa-to-serosa) and 90° (each 
layer scanned independently) orientations.  Signals are also compared to the histological layers and 
primary composition of each layer.  
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Chapter 5.  Pig Experiments 
 
5. Chapter Introduction 
This chapter describes the results obtained with a prototype USCE device in vivo.  The 
purpose of these proof of concept experiments was to address the feasibility of USCE in 
the gastrointestinal (GI) tract.  The primary clinical endpoint of this series of experiments 
was to determine whether sufficient coupling occurred between the capsule transducer(s) 
and the mucosa to generate a transmural microultrasound (µUS) bowel image in a suitably 
large mammal. 
 
5.1. In Vivo Results 
A total of 18 in vivo experiments were carried out with SonoCap, a tethered USCE 
prototype.  Experiments were conducted in the oesophagus (N=6) and small bowel 
(N=12) in a living, anaesthetised pig.  Scans were done in both static and dynamic capsule 
modes.  Static imaging involved parking the capsule in a single position and scanning for 
60 seconds.  The dynamic mode involved operator retrieval or ‘pullback’ of the capsule 
with simultaneous imaging during motion.  The purpose of the experiments was to 
determine whether the transducer(s) maintained contact with the bowel wall.  It should 
be noted that capsule transducers were subject to movement due to normal physiologic 
activities such as bowel peristalsis, respiration, vessel pulsation and random muscle 
twitches.  Furthermore, manual pullback could not be finely controlled and capsule speeds 
varied. 
All case images are presented in ‘Jet’ colour format, showing hyperechoic (e.g. red-
orange), hypoechoic (e.g. yellow-light blue) and anechoic (e.g. dark blue) signals.  
 
5.1.1. Oesophagus 
The prototype capsules were tested in three different stationary (i.e. static) oesophageal 
positions (e.g. distal, mid and proximal).  The distal position equated to the 
gastroesophageal junction (GOJ) and the proximal position was located just below the 
shared area with the trachea (i.e. hypopharynx).  Figure 5.1 represents a static oesophageal 
scan taken at the distal GOJ position for 60 seconds.  The presence of potential tissue 
signals indicated that transducer to tissue coupling occurred.  
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Figure 5.1.  Static image of the gastroesophageal junction (GOJ) by a prototype ultrasound capsule 
endoscope (USCE) which used a single element 30 MHz transducer.  Ultrasonic signals were depicted 
as hyperechoic (e.g. red-orange), hypoechoic (e.g. yellow-light blue) and anechoic (e.g. dark blue).  
Multiple A-scans were taken over a period of 60 seconds and compiled to create the figure.  A-scans 
were averaged and filtered to remove the transducer pulse signal (i.e. ringdown) and improve the signal-
to-noise ratio (SNR).  Areas without a pulse signal revealed a tissue signal (dashed white box).  The 
presence of a tissue signal indicated that good contact occurred between the transducer and tissue. 
 
 
Figure 5.2.  Dynamic scan of the oesophagus from the gastroesophageal junction (GOJ) to just below 
the hypopharynx.  Scans were using a tethered prototype ultrasound capsule endoscope (USCE) with a 
single element 30 MHz transducer.  Ultrasonic signals were depicted as hyperechoic (e.g. red-orange), 
hypoechoic (e.g. yellow-light blue) and anechoic (e.g. dark blue).  Multiple A-scans covering the 33 cm 
scan length were taken during the 60-second pullback.  A-scans have been averaged and filtered to 
remove the transducer pulse signal and improve the signal-to-noise ratio (SNR).  Areas without a pulse 
signal revealed a tissue signal (dashed white box).  The presence of a tissue signal indicated that good 
contact occurred between the transducer and tissue for the length of the pullback. 
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The results of the dynamic oesophageal scan are represented by Figure 5.2.  In this 
particular case, the capsule was pulled back for 60 seconds from the GOJ to the 
hypopharynx over a distance of ≈33 cm.  Tissue signals were present throughout the 
length of the scan.  This indicated that the capsule transducer(s) maintained constant 
contact with the tissue during the length of the pullback. 
 
5.1.2. Small Bowel 
The capsule was introduced directly into the small bowel via a surgically created stoma 
which bypassed the oesophagus and stomach.  Both static and dynamic scans were 
performed. 
Static images of the bowel are presented in Figure 5.3.  The capsule was placed into the 
small bowel and advanced approximately 20 cm beyond the stoma.  Three sets of static 
images were recorded at 20, 13 and 6 cm from the stoma.  Scans were performed over a 
period of 60 seconds and the resultant B-scan was created from the multiple A-scans.  
Good transducer to tissue contact was noted in the B-scans based on the appearance of 
tissue signals.  
 
Figure 5.3.  Static image of the small bowel by a prototype ultrasound capsule endoscope (USCE).  
Scans were achieved using a capsule-based single element 30 MHz transducer.  Ultrasonic signals were 
depicted as hyperechoic (e.g. red-orange), hypoechoic (e.g. yellow-light blue) and anechoic (e.g. dark 
blue).  Multiple A-scans taken over a period of 60 seconds were compiled to create the figure.   A-scans 
have been averaged and filtered to remove the transducer pulse signal and improve the signal-to-noise 
ratio (SNR).  Areas without pulse signal have revealed a tissue signal (dashed white box).  The presence 
of a tissue signal indicated that good contact occurred between the transducer and tissue. 
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Figure 5.4.  Dynamic image of the small bowel by a prototype ultrasound capsule endoscope (USCE).  
Scans were achieved using a capsule-based single element 30 MHz transducer.  Ultrasonic signals were 
depicted as hyperechoic (e.g. red-orange), hypoechoic (e.g. yellow-light blue) and anechoic (e.g. dark 
blue).  Multiple A-scans taken over a period of 70 seconds were compiled to create the figure.  The 
presence of a tissue signal (dashed white box) indicated that good contact occurred between transducer 
and tissue.   
Dynamic images of the small bowel are presented in Figure 5.4.  The capsule was inserted 
into the stoma and advanced approximately 20 cm from the stoma.  The capsule was then 
pulled back for 60 seconds.  Again, good transducer to tissue contact was noted in the 
resultant B-scan, as indicated by tissue signals.    
 
5.2. Shenzhen Capsule 
Imaging results were also achieved using an alternative USCE.  This tethered prototype 
was designed and manufactured by colleagues at Shenzhen University (Figure 5.5) [213], 
[214].  This device consisted of a 10 x 30 mm capsule.  Unlike SonoCap where the 
transducers made direct tissue contact, the 30 MHz Shenzhen transducer was separated 
from the tissue by an acoustic window at a distance of ≈2 mm.  In order to generate a 
360° image, the transducer oscillated between 0° and 360° in an alternative clockwise and 
counter clockwise manner.  
The results showed coupling between the capsule’s acoustic window and transmural 
images of the oesophagus and small bowel were captured (Figure 5.6).  Oesophageal 
results showed a single ultrasonic layer.  An extra adventitial/serosal structure was also 
detected.  This structure may have represented either a lymph node or blood vessel due 
to its cystic appearance.  Images from the small bowel showed three distinct ultrasonic 
layers.   
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Figure 5.5A-B.  A) Capsule schematic and (B) prototype ultrasound capsule endoscope (USCE) 
designed by colleagues at Shenzhen University.  The 10 x 30 mm capsule used a 30 MHz single element 
transducer that oscillated 360°, which was driven by an alternating motor.  The transducer was housed 
inside the capsule and separated from the tissue by ≈2 mm by an acoustic window.  Power and data 
transfer were done via the capsule tether.  Figures adapted from Qiu et al. [214]. 
 
Figure 5.6A-B.  Static grey scale ultrasound images of a pig’s oesophagus (A) and small bowel (B).  
Both results demonstrated adequate capsule to tissue coupling.  Both transducer (red circles) and 
coupling medium (green arrows) were isolated from direct tissue contact by an acoustic window. 
Ultrasound signals passed through an acoustic window (red brackets) in both pulse and echo modes.  
Both results demonstrated adequate capsule to tissue coupling.  This resulted in good ultrasound 
representation of the tissue.  This included distinct hyper/hypoechoic ultrasonic layers in the small bowel 
(red numbers 1-3) representing histologic layers.  Furthermore, associated anatomic structures such as a 
vessel or node were seen in the periphery of the oesophagus (red asterisk).  
90 
 
5.3. Discussion 
The purpose of the experiment discussed in this chapter was to test the feasibility of USCE 
in vivo. Specifically, the experiments were designed to determine whether adequate 
transducer to bowel wall contact occurred.  Direct contact was required in order to 
generate transmural images.   
This experiment demonstrated that satisfactory coupling occurred between the transducer 
and tissue and generated µUS bowel wall images.  Good contact was demonstrated in the 
oesophagus and small bowel under static and dynamic conditions.  These observations 
were an important milestone in providing crucial evidence regarding the feasibility of 
USCE as a diagnostic device [192].  Further evidence of USCE feasibility was observed 
using the alternative designed Shenzhen capsule.  Satisfactory transmural tissue 
visualisation was achieved and included distinct small bowel ultrasonic layers and 
associated oesophageal structures.  
The next step in USCE development is to improve image quality.  It was evident that the 
prototype capsules were unable to clearly delineate ultrasonic tissue layers despite 
evidence of good tissue coupling.  This issue may have arisen from the close proximity 
of the tissue and transducer [192].  Correcting this issue can be achieved by narrowing 
the focal distance of the transducers.  This can be achieved by either further recessing the 
transducer(s) into the capsule or reducing the focal distance during transducer fabrication.  
There was some indication of ultrasonic layering, however, it is not known whether the 
acoustic layers corresponded to histologic bowel layers, neighbouring structures (e.g. 
adjacent bowel loops) or both.  Shenzhen capsule tissue contact was facilitated by the 
acoustic window of the capsule.  The 2 mm distance between the transducer and tissue 
assisted in producing better images and detecting distinct ultrasonic layers.  This placed 
the tissue closer to the 8 mm focal distance of the transducer.  
 
5.4. Summary and Conclusion 
The results from this experiment demonstrated the feasibility of USCE in vivo.  
Establishing transducer to tissue contact was crucial step in USCE development.  
Insufficient contact would have compromised image generation and negatively affected 
USCE diagnostic capabilities.  Proof of concept was achieved in vivo by two capsule 
prototypes.  Further USCE development will require improved capsule and/or transducer 
design to improve tissue imaging.   
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Chapter 6.  Mouse Experiments 
 
6. Chapter Introduction 
This chapter describes the results of mouse gastrointestinal (GI) inflammation 
experiments.  The purpose of these experiments was twofold.  The first objective was to 
determine whether high resolution microultrasound (µUS) could detect GI inflammation.  
The second objective was to determine the lowest grade of inflammation detectable.  The 
results are reported per stage, which comprise Stages 1A, 1B, 2, 2B and 3.  Stage 1 was 
a pilot study to determine the ability of μUS to detect overt (i.e. visually perceptible) 
inflammation.  The aim of Stages 2 and 2B was to identify the lowest grade of 
inflammation detectable by μUS. The goal of Stage 3 was to identify the lowest grade of 
inflammation detectable by μUS in a randomised control trial (RCT). 
 
6.1. Stage 1A and 1B 
The purpose of Stages 1A and 1B was to determine the ability to detect high grade 
inflammation.  Stage 1A was an all-male group (N=5) and four mice were treated with 
5% (w/v) dextran sodium sulphate (DSS) in drinking water ad libitum.  Stage 1B was an 
all-female group (N=5) and four mice were treated with 5% (w/v) DSS in drinking water 
ad libitum.  Clinical information, including individual responses to DSS, are presented in 
Table 6.1. 
 
Table 6.1.  Stage 1A (top) and 1B (bottom) clinical response to dextran sodium sulphate (DSS). Blood 
per rectum (BPR), blood in stool (Stool) and discomfort (e.g. nest soiling, piloerection, hair removal and 
abnormal gait). 
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Baseline scans were done on untreated mice for both Stages 1A and 1B.  Visually, 
baseline caecal tissue was uniformly translucent and negative for signs of blood (Figure 
6.1).  The µUS scan showed mixed echoic signals with three distinct layers.  The acoustic 
layering was hyperechoic-hypoechoic-hyperechoic.  This pattern was consistent along the 
length of the scan, with the transducer perpendicular to the tissue.  Tissue width was 
relatively uniform at ≈0.2 mm.  Histology revealed the caecum to be well-organised 
architecturally and morphologically uniform with a continuous, uninterrupted epithelial 
cell layer.  Baseline small bowel tissue was uniformly translucent (Figure 6.2).  Bowel 
vessels were visible.  The µUS scan was performed across the short axis of the bowel.    
The resultant image was a mixed hyperechoic-hypoechoic image.  Hyperechoic signals 
were predominately seen at deep serosal levels, which provided a degree of acoustic 
layering to the scans.  A central, deep serosal hyperechoic signal corresponded to the fatty 
mesentery.  The oblique histology cut appeared relatively normal, however, the angle of 
the cut blurred the division between the mucosa (M) and submucosa (SM) and the small 
bowel lacked characteristic villi.  Nevertheless, bowel morphology, architecture and the 
cell population appeared to be normal.  The baseline colon also appeared translucent with 
multiple folds that radiated out from a central trough (Figure 6.3).  The µUS scan showed 
mixed signals ranging from anechoic to hyperechoic.  At 37 MHz, µUS was able to 
distinguish colonic folds.  The frequency was also sensitive enough to depict layering at 
the level of the muscularis propria (MP) and serosa (S).  Although not apparent in Figure 
6.3, hyperechoic signals were found at all levels of the bowel wall and not just at deep 
levels.  The accompanying histology slide appeared well organised and showed normal 
morphology.  The tissue was cut through a colonic fold and demonstrated a clear division 
between the M and SM.  The cellular composition of the M appeared to be dominated by 
epithelial colonocytes and goblet cells (GC) that greatly outnumbered interstitial support 
cells.  The M also contained an aggregate of lymphoid tissue that may have represented 
the colonic portion of GALT.  The aggregation appeared well organised with clear 
borders between it and neighbouring tissue.  The MP appeared well structured and 
organised.   
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Figure 6.1A-C.  Caecum result from a healthy mouse. (A) Dissection microscope image of the caecum 
showed a translucent organ without visible pathologic defects.  (B) Haematoxylin and eosin histology 
revealed tissue that was architecturally and morphologically normal in appearance.  The tissue was non-
oedematous and consistent in appearance.  (C) The corresponding microultrasound (µUS) scan was also 
predominately uniform in appearance.  The scan was mixed hyperechoic (red-yellow) and hypoechoic 
(blue-green) with a central anechoic (dark blue) stripe forming three distinct layers.   Angulation of the 
tissue appeared to have reduced the ability of µUS to discern all three layers, which is noted on the left-
hand side of the scan. 
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Figure 6.2A-D.  Sample baseline small bowel result from an untreated mouse. (A) Photograph of the 
small bowel.  The bowel was predominately translucent, permitting visualisation of the vasculature 
and the deep, fatty mesentery.  While the tissue vasculature was seen, there were no signs of 
haemorrhagic lesions.  Food residue (red arrow head) was also present, which could present as a 
superficial hyperechoic signal.  (B) A haematoxylin and eosin slide of an oblique tissue cut. This slide 
lacked features normally associated with healthy tissue, such as prominent villi.  The poor state of the 
tissue may have been due to tissue necrosis during scanning or inadequate fixation. (C) A 
perpendicular cut of a haematoxylin and eosin slide.  Although this cut lacked villi, the submucosa 
(SM) was present.  Crypts were tightly packed and lined with columnar epithelium.  (D) Short axis 
microultrasound (µUS) scan of the small bowel featuring the mesentery (red arrow).  The tissue signal 
was predominately hypoechoic (e.g. blue-green) with hyperechoic (e.g. red-yellow) elements in the 
deeper layers.  The fatty mesentery was represented by the deep hyperechoic signal (red arrow). 
Mucosa (M), muscularis mucosae (Mm), muscularis propria (MP), serosa (S). 
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Figure 6.3A-C.  Sample colon result from an untreated mouse. (A) Photograph of the proximal colon.  
Tissue was translucent and contained numerous folds along a central trough. Notably, there were 
minimal amounts of debris present.  (B) Haematoxylin and eosin slide, the tissue was highly organised 
with clear histologic layers.  The epithelium along the microfolds was continuous and housed numerous 
pale purple goblet cells.  A cluster of immune cells (green arrow) was also present.  This was most likely 
a normal (i.e. non-inflammatory) lymphoid nodule and not a collection of reactive cells.  (C) 
Microultrasound (µUS) scan of the proximal colon across the short axis of the bowel.  Signals ranged 
from hyperechoic to anechoic.  The resultant image nicely demonstrated the colonic folds.  The image 
also showed deep tissue layering, particularly on the left-hand side.  An anechoic layer was present just 
above the mixed hyperechoic-hypoechoic serosa. Mucosa (M), muscularis mucosae (Mm), submucosa 
(SM), muscularis propria (MP).      
All Stage 1A treated mice reached a humane endpoint by Days 5 (N=2) and 6 (N=2).  
Clinical signs of discomfort, which included behavioural indications of discomfort such 
as nest soiling, were observed (Table 6.1).  Overt haemorrhagic lesions were noted post-
mortem in the caecum of all four mice.  The small bowel and colon of all mice were 
visually judged to be lesion free.  Tissue with lesions was photographed, scanned and 
prepared for histological analysis (Figure 6.4). 
  
 
 
96 
 
79 
 
80 
In general, caecal lesions from Stage 1A appeared as bright red haemorrhagic 
lesions.  The central portion of the lesions appeared to have breached the mucosal 
layer.  The peripheral areas of the wound were muted red, indicating that these areas were 
most likely subsurface.  µUS scans showed a hyperechoic (red-yellow) signal 
corresponding to the lesion.  The hyperechoic signal was full thickness (i.e. M to S).  
 
 
 
Figure 6.4A-H.  Sample results from a Stage 1A mouse treated with dextran sodium sulphate (DSS) for 
five days.  (A-B) Photographs of the caecum and associated lesion.  Grossly, the lesion manifested as a 
bright red haemorrhagic wound that appeared to have breached the mucosal surface.  At the periphery 
of the wound, the colour appeared muted, which possibly indicated a subsurface component to the lesion.  
(C) Haematoxylin and eosin staining revealed acute transmural inflammation with white cell infiltrates 
extending from the mucosa (M) to serosa.  This was judged as severe transmural inflammation and 
equated to a grade of 3.  There was also considerable morphologic change in relation to mucosal 
destruction, tissue oedema and the presence of extravasated red blood cells. (D-F)  Magnified images of 
the image C, roughly mid-slide (D-Mucosa, E-Submucosa and F-Muscularis Propria).  (G) 
Microultrasound (µUS) scan of the caecal lesion.  This is a representative image slice which was 1 of 56 
slices produced in total.  The image showed a transmural hyperechoic (e.g. red-yellow) patch.  The 
hyperechoic signal involved both mid and deep tissue layers, but not the uppermost superficial layer.  
This may have indicated the scan was at the periphery of the lesion and inflammation had not breached 
the surface.  (D) Volumetric reconstruction using all 56 slices from the scan.  The image was created 
using Volocity® (Volocity 5.5.1, PerkinElmer Inc., Waltham, US). The extent of the hyperechoic lesion 
is indicated by the dashed red line and includes subsurface components. Key: Muscularis mucosae (Mm), 
submucosa (SM), muscularis propria (MP). 
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Haematoxylin and eosin (H&E) histology of 20171129M2 (Figure 6.4E-F) demonstrated 
acute transmural inflammation with white cell infiltrates extending from the M to S.  
Based on the large presence and the transmural infiltration of white cells, the lesion was 
judged to be severe, transmural and graded as a 3.  There was also considerable 
morphologic change with regard to mucosal disruption, tissue oedema and the presence 
of extravasated red blood cells. 
Stage 1B mice reached humane endpoints by Days 4 (N=2) and 5 (N=2).  Visible 
haemorrhagic lesions were noted in the small bowel (N=1), caecum (N=1) and colon 
(N=1) of three individual mice (i.e. one lesion per animal).  One mouse was lesion free 
upon visual inspection.    
The small bowel sample with the visible lesion was photographed, scanned and prepared 
for histological analysis (Figure 6.5).  On visual inspection, the small bowel lesion was 
located in the mid-ileum and appeared to have two small haemorrhagic lesions along the 
mesentery.  Approximately mid-tissue, part of the ileum appeared to have a muted red 
appearance compared to the rest of the tissue.  This was judged to potentially indicate 
inflammation and a 37 MHz scan was performed along the long axis.  The tissue was 
predominately hypoechoic, unless the lesion or fatty mesentery, which were hyperechoic, 
were in the scan plane.  The lesion appeared transmural with the mesentery located on the 
deep (i.e. serosal) side of the bowel.  Histology of the ileum was compromised, possibly 
due to poor preservation and an oblique cut.  Determining whether the tissue was inflamed 
was not possible.  A small cluster of immune cells was noted; however, this may have 
represented a baseline feature.   
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Figure 6.5A-C.  Sample small bowel result from a Stage 1B mouse treated with dextran sodium sulphate 
(DSS) for four days.  (A) Photograph of the small bowel at mid-ileum.  The tissue appeared to have two 
pinpoint haemorrhagic lesions along the mesentery.  Additionally, a slight opaque discolouration is 
encircled by the red line. It was suspected that this represented an area of inflammation.  (B) 
Haematoxylin and eosin slide of the opaque area.  Poor preservation and an oblique cut compromised 
tissue interpretation.  Familiar landmarks such as the submucosa (SM) and signature villi of the small 
bowel were absent.  The cause, whether due to necrosis during scanning, inflammation or poor fixation, 
was unknown.  There was a cluster of immune cells present in the deep mucosa (green arrow).  
Determining whether the cluster was a baseline structure or induced was not possible.  (C) The opaque 
area was scanned at 37 MHz along the long axis of the ileum.  The scan was roughly mid-lesion, which 
is marked by the dashed red line in Figure 6.3A.  The resultant image showed an area of enhanced 
echogenicity.  The signal appeared transmural, which indicated an inflammatory response had occurred, 
however, this could not be definitely correlated by histology.    
The proximal colonic lesion was bright red centrally with a muted red periphery (Figure 
6.6).  Again, this indicated the central portion breached the surface layer while the 
peripheral areas remained subsurface.  The lesion was located along the mesentery of the 
colon.  There was also a high degree of faecal debris.  The µUS scan was mixed signal 
with two superficial hyperechoic signals.  One signal corresponded to the lesion location 
whilst the second signal may have depicted the faecal debris.  Histology revealed a surface 
to mid-tissue acute inflammatory process that spared the deeper MP.  The inflammatory 
grade was considered 2 solely due to the location of infiltrates.  Normal surface features 
were absent, including the loss of the epithelial lining. 
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Figure 6.6A-C.  Sample colon result from a Stage 1B mouse treated with dextran sodium sulphate (DSS) 
for five days.  (A) Photograph of the proximal bowel and associated lesion.  The tissue was characterised 
by multiple folds.  There was a bright red lesion present on the mesentery.  The lesion appeared as a 
bright red spot which was muted in the peripheral areas.  (B)  Haematoxylin and eosin staining revealed 
acute inflammation with white cell infiltrates which extended from the mucosa (M) to submucosa (SM).  
The muscularis propria (MP) appeared to be free from infiltrates, thus the inflammatory grade was 
considered 2 solely due to the location of infiltrates.  The mucosal epithelium was compromised and 
accompanied by the loss of normal features, but did not extend beyond the M.  The representative 
microultrasound (µUS) slice was from the dashed red line on the camera image.  The signal was mixed, 
ranging from hyperechoic to anechoic.  The hyperechoic signal on the right side corresponded with the 
location of the lesion.  In this instance, the signal was not transmural.  It extended from the surface to 
mid-tissue.  There was a second superficial hyperechoic signal located on the left side of the tissue.  This 
signal potentially corresponded to the debris seen on the camera image.  N.B. It should be noted that this 
slide was potentially incorrectly labelled and attributed to the second mouse day 5 mouse scanned that 
day.  This was due to a clerical error.  Nevertheless, the histology slide represents an inflamed colon 
after treatment with DSS after five days.  Muscularis mucosae (Mm). 
 
The results from Stages 1A and 1B indicated that µUS could detect overt inflammation. 
This satisfied the criteria for advancing to Stage 2.   
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6.2. Stage 2 
The purpose of Stage 2 was to determine the lowest grade of inflammation detectable by 
µUS. Mice were treated with 5% DSS in drinking water.  Each day, one pair of mice, one 
female and one male, were culled and scanned.  This provided data for 12 mice (six males 
and six females).  Culls began on Day 0 (i.e. baseline) and ended on Day 4.  This created 
a variable length of exposure to DSS and induced graduated inflammatory levels 
depending on the length of exposure.  No animal reached the predetermined humane 
endpoints (Table 6.2).  Behavioural changes were not encountered until Days 3 and 4.  
Positive GI bleeding, confirmed at post-mortem, was not encountered until Day 4 and 
was present in both mice.  
 
 
Table 6.2.  Stage 2 clinical response to dextran sodium sulphate (DSS). Blood per rectum (BPR), test 
for blood in stool (Stool) and discomfort (e.g. nest soiling, piloerection, hair removal and abnormal 
gait). 
 
 
 
 
 
 
 
 
 
 
Table 6.3.  Stage 2 histological response to dextran sodium sulphate (DSS).  ‘X’ indicates that the slide 
was illegible due to poor preservation, missing during shipping or poorly digitised (i.e. out of focus). 
 
 
ID Sex Trial 5% DSS Cull Day BPR Stool Discomfort
20180219M1 F 2 - 0 - - -
20180219M2 M 2 - 0 - - -
20180220M1 M 2 + 1 - - -
20180220M2 F 2 + 1 - - -
0180220M3 F 2 + 1 - - -
20180221M1 F 2 + 2 - - -
20180221M2 M 2 + 2 - - -
20180221M3 M 2 + 2 - - -
20180222M1 M 2 + 3 - - -
20180222M2 F 2 + 3 - - +
20180223M1 F 2 + 4 + - +
20180223M2 M 2 + 4 + - +
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Figure 6.7A-E.  Colon results from Stage 2.  Microultrasound (µUS) of scans of an untreated mouse (A) 
and treated mouse after four days of 5% dextran sodium sulphate (DSS) (B).  The baseline scan signals 
were predominately hypoechoic (e.g. blue-green) with scattered hyperechoic (e.g. red-yellow) and 
anechoic (e.g. dark blue) elements.  Hyperechoic elements were largely found in the deep tissue, forming 
distinct layers in conjunction with the anechoic signals.  Superficial hyperechoic signals may have been 
due to debris signals.  Tall colonic folds could be easily seen across the short axis of the bowel.   The 
scan from the treated mouse was also a mix of all three signal types.  The hyperechoic signals were 
shifted more superficially and appeared more scattered.  Nevertheless, the deep tissue layering was 
preserved.  Transmural dimensions appeared thicker and colonic folds also appeared shortened, which 
may have resulted from oedema.  Corresponding haematoxylin and eosin slides of the untreated colon 
(C) and treated mouse (D).  Despite its poor state of preservation, the untreated colon appeared free from 
inflammation.  Long colonic folds could also be seen on histology which accorded with the µUS scan.   
Histology from the treated colon demonstrated inflamed section of bowel.  (E) Confluent white cell 
infiltration at the level of the mucosa (M) and submucosa (SM) were seen in a magnified section (Image 
D, blue arrow). Infiltration into the muscularis propria (MP) was also noted (green arrow).  Inflammation 
was graded as Grade 2 with minor transmural elements (i.e. Grade 3).  The mucosa appeared largely 
intact and the colonic folds could be identified, albeit stunted, as seen in the µUS scan.  Additionally, 
the tissue appeared thickened transmurally. 
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No overt (i.e. haemorrhagic) lesions were noted on post-mortem optical examination, 
which included the mice with blood per rectum.  Scanning failed to reveal any appreciable 
difference between untreated and treated mice.  On the other hand, histology 
demonstrated variable grades of inflammation and was noted as early as Day 1 (Table 
6.3).  Early onset inflammation was confined to the M and graded 1.  The lesions were 
patchy and very small (e.g. <100 µm) in size.  Further histological analysis showed an 
evolving inflammatory process resulting in Grades 2 (i.e. M + SM) and 3 (i.e. transmural) 
being encountered by Day 4.  A qualitative µUS comparison between Day 0 and Day 4 
failed to reveal any difference despite histological evidence of grade 2-3 inflammation on 
Day 4 (Figure 6.7).  Nonspecific signs of inflammation such as tissue oedema could be 
noted on µUS scans. 
The decision to advance from Stage 2 to 3 before having all the data from stage 2 became 
necessary because of a very long delay in being able to process the histology slides from 
stage 2 samples.  The University of Dundee histology slide scanner and associated 
software were not available due to technical issue and it took a while before it emerged 
that alternative services would have to be used and I sent my slides to University of 
Glasgow to be scanned.  The time required to then receive the scans, meant that the 
scheduled start for Stage 3 occurred before a thorough analysis was completed.  Thus, I 
made the decision to progress to Stage 3 based on positive results from Stage 1A/B and 
the availability of the appropriate animals at the time (e.g. sufficient numbers, acceptable 
age, and sex matched).  A further delay would have required additional animals to be bred 
and reared until an acceptable age. 
6.3. Stage 3 
Stage 3 was done to determine the lowest inflammatory grade detectable in a RCT.  The 
author was blinded to treatment status.  This involved 16 mice in total (N=16).  Treated 
mice were provided 5% DSS (w/v) in the drinking water ad libitum.  All mice underwent 
daily observations which included health assessment, weigh-in and faecal examination, 
with records remaining sealed until the study was completed (Table 6.4).  Behavioural 
information related to GI inflammation was not recorded in this instance. 
Blinded histological review of the tissue confirmed inflammation (Table 6.5).  
Importantly, low grade inflammation was detected in non-treated mice.  The baseline 
presence of inflammation may have been due to bacterial contamination in the mouse 
facility.  It was reported that mice were harbouring Klebsiella (K. oxytoca, K. 
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pneumoniae) following faecal analysis [215].  Klebsiella is considered an opportunistic 
pathogen which may have had a baseline affect mouse bowel [216].  Good tissue 
preservation and H&E staining was consistently seen with the colon and to a lesser 
degree, the caecum.  This permitted reliable grading of the inflammatory state of colonic 
tissue with a good degree of confidence. The small bowel samples, however, did not 
preserve well and were judged to be a poor indicator of inflammation and grading. 
µUS results were reviewed without knowledge of treatment status. By comparing results 
against one another, it was determined that there were no definitive qualitative differences 
between the scans.  The results were also compared against other baseline (i.e. DSS 
negative) scans which, again, resulted in no appreciable difference between scans.  This  
indicated that µUS at 37 MHz could not distinguish between healthy tissue and mild 
grades of inflammation in mice. 
 
 
 
 
 
 
 
Table 6.4.  Stage 3 clinical response to dextran sodium sulphate (DSS). Blood per rectum (BPR), blood 
in stool (Stool). 
 
 
Table 6.5.  Stage 3 histological response to dextran sodium sulphate (DSS). Length of treatment (Day), 
treated (+), healthy (0), mucosal inflammation (1), mucosal and submucosal inflammation (2), 
transmural inflammation (3), unknown (x). 
ID Sex Trial 5% DSS Cull Day BPR Stool
20180906M1 F 3 - 0 - -
20180906M2 F 3 - 0 - -
20180907M1 F 3 + 2 - -
20180907M2 F 3 + 2 - -
20180910M1 F 3 + 3 - -
20180910M2 F 3 - 0 - -
20180911M1 F 3 + 4 - -
20180912M1 M 3 + 2 - -
20180912M2 M 3 + 2 - -
20180914M1 F 3 + 4 + -
0180914M2 F 3 + 4 + -
20180917M1 M 3 - 0 - -
20180917M2 M 3 - 0 - -
20180918M1 M 3 + 4 + -
20180919M1 F 3 + 2 - -
20180919M2 F 3 + 2 - -
ID DSS Day Caecum Colon Small Bowel
20180906M1 - 0 0 1 0
20180906M2 - 0 1 1 0
20180907M1 + 2 0 2 1
20180907M2 + 2 2 2 x
20180910M1 + 3 1 3 0
20180910M2 - 0 0 1 0
20180911M1 + 4 1 2 0
20180912M1 + 2 2 1 0
20180912M2 + 2 0 2 1
20180914M1 + 4 1 3 1
20180914M2 + 4 1 0 1
20180917M1 - 0 0 0 0
20180917M2 - 0 0 1 1
20180918M1 + 4 1 2 1
20180919M1 + 2 2 1 1
20180919M2 + 2 2 1 1
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6.4. Stage 2B 
Stage 2B occurred after Stage 3 as the higher frequency transducers were not available 
until after the completion of Stage 3.  Stage 2B was conducted in a similar manner as 
Stage 2.  The purpose of Stage 2B was to determine whether lower grades of inflammation 
could be detected using a higher frequency transducer.  The frequency was increased from 
37 MHz to 62 MHz, which provided enhanced image resolution. Inflammation was 
generated using the protocol from Stage 2 with culls occurring on Days 0, 2, 3 and 4.  Day 
1 was omitted due to a small sample size (N=7) and the experience that nascent 
inflammation was too difficult to detect ultrasonically and be confirmed with histology.  
Stage 2B consisted of three females and four males, of which two females differed 
genetically from the standard wild-type mice (Table 6.6).  The two females were 
heterozygote mutants for the adenomatous polyposis coli (ApcMin/+) gene, a murine model 
of human familial adenomatous polyposis (FAP).   It was suspected that ApcMin/+ may 
display increased sensitivity to DSS, otherwise the inclusion of these mice was not 
expected to dramatically affect the results [217], [218]  
µUS results at 62 MHz demonstrated an enhanced resolution over the previously 
employed 37 MHz, as expected (Figure 6.8).  The higher frequency was able to discern 
smaller microstructures and provided improved resolution in both the axial and lateral 
direction.  Immediately noticeable was the reduction of anechoic signals within the tissue.   
There was also an improved definition of the deep tissue layers of the colon at the level 
of the MP and S.  This was indicated by the consistent presence of a hypoechoic band 
that resided between two hyperechoic stripes.  No other ultrasonic layers, such as the 
interface between the M and SM, were noted. 
 
Table 6.6.  Stage 2B clinical response to Dextran Sodium Sulphate. Dextran Sodium Sulphate (DSS), 
Blood Per Rectum (BPR), Blood in Stool (Stool), Blood in stool at post-mortem examination (*) and 
discomfort (e.g. nest soiling, piloerection, hair removal and abnormal gait). 
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Inflammation was detected by histology (Table 6.7).  Despite the improved resolution, 
definitive µUS signs of inflammation could not be discerned.  A comparison of an  
untreated Day 0 mouse against two treated mice with histological signs of inflammation 
failed to reveal any acoustic indications of inflammation (Figure 6.9). 
 
Figure 6.8A-F.  Comparison of scans at 37 MHz (left column) against 62 MHz (right column) for the 
three anatomic sites.  Scans are of the small bowel (A-B), caecum (C-D) and colon (E-F).  Scans are of 
untreated mice from Stages 2 and 2B.  Images at 62 MHz demonstrated enhanced resolution.  Details 
from deeper tissue layers can be noted in all three anatomic sites due to the improved axial and lateral 
resolution.  In the 62 MHz colon scan (F), the consistent presence of a deep hypoechoic band that resided 
between two hyperechoic stripes.   
 
 
Table 6.7.  Stage 2B histological response to dextran sodium sulphate (DSS).  ‘X’ indicates that the slide 
was illegible due to poor tissue preservation. 
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Figure 6.9A-H.  Microultrasound (µUS) and histology results from Stage 2B.  Representative results 
are from the distal colons of an untreated mouse (A and D) and two mice after four days of dextran 
sodium sulphate (DSS) treatment (M1: B, E and F, M2: C, G and H).  Both treated mice demonstrated 
histological signs of inflammation.  Inflammatory cell infiltration for M1 (E) was grade 2, but patchy 
(red arrows). (F) Magnified area from left red arrow. Inflammatory cell infiltration for M2 (G) was also 
grade 2 but was considerably larger and confluent (double-headed red arrow, H Magnified area at yellow 
arrow).  The untreated mouse colon (D) was unremarkable and appeared to be healthy and without white 
cell infiltrates.  However, the associated µUS scans of M1 (B) and M2 (C) failed to reveal any definitive 
signs of inflammation when compared to the untreated mouse (A).        
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6.5. Discussion 
The first objective of this set of experiments was to determine whether high resolution 
µUS could detect GI inflammation.  The second objective was to determine the lowest 
grade of inflammation detectable.  Initial results indicated that detection of high grade 
(i.e. severe), transmural inflammation was possible, and coincided with clear optical signs 
of inflammation in the form of visible bright red haemorrhagic lesions.  However, my 
experiment failed to reveal any direct µUS signs of low grade (i.e. milder) inflammation 
using 37 and 62 MHz.  
Initially, µUS analysis was hampered by the presence of faecal debris which had the 
potential to be viewed as a lesion as it produced superficial hyperechoic signals.  
Improved cleaning methods reduced the amount of debris and improved the ability to rule 
out debris-generated signals.  This was done by aligning the scan results with camera 
images using landmarks visible in both modalities (e.g. air bubbles or specific anatomic 
cues).  µUS signs of debris that corresponded with optical signs were discounted as false 
positive and unexplained signals that remained were considered to potentially indicate 
inflammation.  However, aligning the suspicious signals with histology proved far more 
challenging.  A significant challenge in this study was the difficulty of precisely aligning 
scan data with histological data.  This was in part due to the scale difference of the two 
modalities.  Histology scales are in µm while µUS scales are in mm.  Furthermore, 
histology slices lacked the large-scale landmarks to assist with matching scan slices.  In 
other words, histology results could only be approximated to either a proximal or distal 
location along an anatomical sample.  With stage 2B tissue samples, I attempted to narrow 
anatomic locations by dividing each tissue sample into quarters.  Each 4 mm quarter 
sample was labelled as proximal, mid-proximal, mid-distal and distal.  The same division 
was also applied to each µUS scan.  This resulted in a slight improvement in aligning the 
two images from both modalities, but a degree of uncertainty still remained.  This 
uncertainty was further exacerbated by the seemingly random hyperechoic signals 
distributed throughout all tissue depths in both treated and untreated tissue.  Without the 
ability to precisely align a scan slice with the corresponding histology slice, hyperechoic 
signals could not be interpreted as true positive (i.e. inflammation) or false positive with 
confidence.   
It is also possible that the detection of low-grade inflammation in mouse bowel is limited 
by the resolution of the two utilised frequencies.  The µUS wavelengths at 37 and 62 MHz 
are 0.04 mm and 0.02 mm, respectively.  Mouse colon wall thickness, as measured by 
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Brückner et al is 0.3 mm (± 0.03) [219].  This means that a µUS wavelength of 0.04 mm 
spans 13% and 0.02 mm spans 6.7% of a mouse bowel wall.  These relatively large 
wavelengths may have been of insufficient resolution and may explain why minute low 
grade lesions could not be detected.  
The primary endpoint of this study was to directly detect acute inflammation via the 
infiltration and accumulation of monocytes and neutrophils.  Nevertheless, other signs, 
such as wall thickening, and fold shortening, of inflammation were observed.  These 
observations were not formally collected given their non-specificity.  However, this does 
not rule out their use as an adjunct to diagnosis.  Radiometric measurements have the 
potential provide additional diagnostic information and can be applied to US scans.  
However, these metrics may not account for residual disease activity, such as acute 
inflammatory cells in the superficial layers, that direct tissue imaging would theoretically 
permit.  As introduced in Chapter 1, it is this approach that can potentially achieve a 
therapeutic endpoint of complete remission.    
 
6.6. Summary and Conclusion 
This chapter described the results of mouse GI inflammatory experiments.  The first 
objective of determining whether µUS could detect GI inflammation was achieved.  The 
results showed that high grade transmural inflammation was detected by a 37 MHz 
transducer.  Further experiments indicated that mild to moderate inflammation could not 
be detected with either 37 or 62 MHz transducers.  Improved alignment between µUS 
and histology could help with cross modality comparisons.  Nevertheless, the detection 
of low-grade inflammation may be beyond the capabilities of the two frequencies used in 
this series of experiments. 
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Chapter 7. Conclusion 
 
7. Chapter Introduction 
This chapter discusses the main findings from each chapter as they relate to ultrasound 
capsule endoscopy (USCE) and the diagnosis and management of gastrointestinal (GI) 
disorders.  Potential avenues of future research are also discussed.  
 
7.1. Crohn’s Disease and Capsule Endoscopy 
Crohn’s disease (CD) is an inflammatory bowel disease (IBD) of the GI tract.  It is 
chronic, progressive and marked by intermittent periods of remission and relapse.  The 
disease can affect any part of the gastrointestinal (GI) tract [1]. 
The prevalence of IBD is estimated at ≈ 0.3% of the population in the UK and another 
1.45 cases per 100,000 persons will be added per year [220].  Roughly a third of the newly 
diagnosed will be under the age of 21 [221].  Despite the illness, patients with CD do not 
appear to have a significantly elevated mortality rate over the general population [222].   
Additionally, patients can experience numerous diagnostic tests including endoscopic 
examination throughout their lives [223]. 
Capsule endoscopy (CE) has emerged as a valuable means of GI examination.  Benefits 
of CE include entire GI tract visualisation, non-invasive administration and good 
tolerance by patients [19].  Due to its benefits, CE is well suited for diagnosis and 
monitoring in IBD, including treatment responses [5].  The latter benefit becomes more 
salient when considering that premature discontinuation of treatment results in residual 
disease, particularly in remote bowel sections.  This illustrates the need for whole bowel 
assessment to guide therapy in order to achieve a complete response [224].  
Currently, CE is not considered a frontline examination due to a number of limitations 
including the reliance on optical imaging.  Optical cameras cannot perform transmural 
cross-sectional imaging nor provide subsurface pathological information. By equipping 
CEs with a means to image subsurface pathology, clinicians could examine the subsurface 
components of the GI tract in its entirety.  This has the potential to move beyond using 
mucosal healing as a therapeutic endpoint and aim at achieving complete histological 
remission [12], [225].  
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Ultrasound CE (USCE) is a potential means of transmural imaging [64].  Furthermore, 
high resolution microultrasound (µUS) has the potential to guide treatment and achieve 
histological remission by means of virtual biopsy [226].   As shown by Fatehullah et al., 
µUS can detect premalignant changes in mutant adenomatous polyposis coli (ApcMin/+) 
mouse small bowel before the onset of optically detectable changes [63].  Based on these 
results, it can be reasonably inferred that µUS may be capable of detecting the massive 
convergence of immune cells that accompanies acute inflammation. 
My research examined a number of facets associated with the development of USCE.  
This work was done in order to fulfil a clinical need for an improved means of diagnosis 
and management of CD. 
 
7.2. Results Discussion 
The following section summarises key findings obtained using human, mice and pig 
tissue, and how these findings advances the development of USCE.  
 
7.2.1. Human 
Results for the human tissue scans indicated that ≈ 35 MHz is an acceptable frequency 
range for human tissue and inclusion into USCE.  Frequencies near 35 MHz provided an 
acceptable balance between depth of tissue penetration and detail.  Scans from Case 1 
illustrated the enhanced imaging capabilities of µUS over the standard 7 – 12 MHz 
clinically used frequencies.  At 34 MHz the number of acoustic layers increased to 9 
layers from the 5 layers visualised with standard frequencies.  Of particular interest was 
the increased level of detail of mucosa.  
At standard frequencies, there are only two distinguishable acoustic layers generated by 
the mucosa [55].  At > 35 MHz there are four layers generated by the mucosa.  These 
include the lamina propria (LP), a major immune effector site, represented by the 2nd and 
3rd acoustic layers.  The muscularis mucosae (Mm) is represented the 3rd and 4th signals 
[227].  This indicates that µUS frequencies have the potential to detect inflammatory 
changes in the mucosal LP.  For example, Nylund et al detected a thickened Mm in CD 
patients which is not normally ultrasonically visible [228].  Additionally, they were able 
to visualise a hypoechoic lymphocyte aggregate at the level of the muscularis propria at 
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10 MHz.  These results are consistent with the hypothesis that ≈ 35 MHz has the potential 
to detect changes associated with inflammation in human GI tissue. 
Although only lightly touched upon, comparing µUS results with histology indicated that 
further work is required.  This would help with understanding the relationship between 
acoustic layers and histologic layers [57].  In addition, scanning tissue in the standard 
mucosal to serosal manner, other orientations were to be a viable means of tissue imaging.  
In fact, scanning each tissue layer independently at 90° to the transducer represents a 
novel technique.  This may assist in determining how the composition of each layer 
contributes to µUS image formation.  
Further research into the acoustic-histologic relationship would also help advance 
concepts in virtual histology.  This is especially pertinent, as it was apparent that µUS 
showed wide morphologic and organisational variation between cases.  Reasons for the 
differences between samples were unknown but may have been due to primary disease, 
comorbidities, age or other factors [210], [211], [229], [230].  Results from Chapter 4 
strongly suggest that a more rigorous comparison of human µUS and histology is 
warranted.  
Results for the human tissue scanning have indicated that µUS is capable of displaying 
tissue with a high degree of detail.  This would indicate that high resolution USCE has 
the potential to provide a means of analysing tissue and associated pathology in situ [64], 
[231].  In order to do so effectively, it will be necessary to correlate µUS signals with 
histology definitively.  Tissue analysis is critical in medical decision making and any new 
means of analysis must be consistent with histology, the current gold standard.  
 
7.2.2. Pig 
Results from both experimental prototype capsules demonstrated that USCE is feasible.  
Sufficient contact occurred between capsule transducers and mucosa to produce a 
transmural bowel image.  
Future work should centre on developing an improved µUS array for inclusion into the 
capsule.  Required improvements need to adjust transducer focus to account for depth of 
regions of interest [206].  For effective imaging of acute inflammation, a transducer 
focused at relatively shallow depths is required.  This is because the LP, the primary 
immune effector site, lies close to the surface.  Also required is a 360° cross-sectional 
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image of the bowel wall to improve USCE diagnostic yield over multiple single element 
transducers.  A ring shaped annular transducer has been suggested as a possible 
configuration to meet this requirement (Figure 7.1) [232].  Based on the results from the 
human tissue trial such a transducer should use a centre frequency of 35 MHz. 
 
Figure 7.1.  Simulated annular image of ex vivo pig small bowel.  The image was processed to form a 
circular image from a flat image.  The image was stitched (red arrow) to simulate a single slice transmural 
ultrasound capsule endoscope view.  Image adapted from Lay et al [232].     
Further pre-clinical development could continue to use pigs as they represent a practical 
large animal model for GI biomedical research [233], [234].  As a monogastric and 
omnivorous animal, the pig shares a high degree of anatomical and physiologic similarity 
with humans.  Most importantly, the calibre of the bowel lumen and bowel wall thickness 
are comparable to humans (Figure 7.2) [235].  
The similarity in bowel dimensions will permit the use of full scale USCE prototypes, 
like those demonstrated here.  Similar bowel dimensions would eliminate the need to 
scale the dimensions of the capsule shell (i.e. 10 mm Ø x 30 mm L).  Furthermore, similar 
bowel wall thickness would permit direct assessment of the capsule µUS frequency 
because µUS wavelengths correspond well between the two species, unlike mouse bowel 
dimensions.  
Pig models of human disease are available including models of IBD based on the use of 
DSS and precancerous conditions such as Familial Adenomatous Polyposis (FAP) pigs 
[233], [236], [237]. 
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Figure 7.2.  Comparitive anatomy and histology of the three organisms used for experiments.  All three 
systems have similar gross anatomical structure from oesophagus to rectum.  Interspecies differences 
can be noted such as the relatively large caecum of the mouse.  Although humans and pigs are 
monogastric and omnivourous; colonic structures differ signigicantly including the characteristic spiral 
colon of the pig.  In terms of gross measurments, pigs and humans exhibit similar bowel diameters and 
wall thickness that is not shared by the mouse.  Microscopically, all three share the same four cardinal 
bowel layers (mucosa, submucosa, muscularis propria and serosa).  Image adapted from T. Kararli [235].   
  
7.2.3. Mouse 
The results from the inflammatory mouse bowel experiments indicate that µUS can detect 
high grade inflammation.  Lower grade inflammation, which would equate to early onset 
or post-treatment residual IBD, was not detectable.  It is possible that the frequencies used 
were an inappropriate scale for the thickness of mouse bowel.  Evidence for this argument 
is the number of acoustic layers revealed in the scans.  At 37 MHz, the maximum number 
of acoustic layers displayed was limited to 3, which were seen predominately in the colon 
scans, nor did the number of visible layers increase when the frequency was raised to 
62 MHz. This was unlike the results from the human colon experiments where higher 
frequencies revealed additional acoustic layers over standard frequencies of 5 - 12 MHz.  
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This suggests that neither 37 nor 62 MHz is suitable for detecting low grade GI 
inflammation in mice. 
Regardless, µUS studies on mouse bowel could be conducted using even higher 
frequencies.  This would help to resolve the potential wavelength to tissue dimension 
issue, and whether enhanced resolution could identify low grade inflammation.  
Alternatively, high resolution imaging can be done with Optical Coherence Tomography 
(OCT).  
OCT operates on the same transmit/receive principle as US but uses light to provide high 
resolution subsurface images (Figure 7.3) [238].  Additionally, OCT has already been 
incorporated into a tethered capsule endoscope and tested clinically.  Gora et al developed 
a OCT capsule to examine the oesophagus and monitor Barrett’s Oesophagus [239], 
[240].  The authors were able to produce highly detailed 3-dimensional images of the 
oesophagus.  Furthermore, OCT represents an attractive modality for facilitating virtual 
biopsy [241], [242].  This is because it can rapidly produce highly detailed (axial 
resolution ~10 µm and lateral resolution ~30 µm) volumetric images.  The primary 
drawbacks are the limited depth of tissue penetration, estimated to be 3 mm maximum 
depending on pressure and probe type [243].  This potentially limits its utility to 
superficial diseases of the mucosa which includes inflammation and neoplasms of 
epithelial origin [244].        
 
Figure 7.3A-B.  Optical Coherence Tomography (OCT) scan of ex vivo pig small bowel.  (A) Image of 
a perfused section of small bowel.  The level of mucosal detail is clear and individual villi (yellow 
arrows) can be discerned.  Also evident is the limited depth of tissue penetration by the light waves.  (B) 
Image of a bowel section post perfusion with 10 µm diameter polystyrene beads (red arrows).  OCT is 
able to detect the subsurface accumulation of beads.  Images created in collaboration in Y. Ling. 
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As discussed in Chapter 6, there was difficulty aligning scan results with corresponding 
histology slices. Simultaneous optical and µUS imaging of the tissue may be a potential 
means of resolving this problem.  Optical images in the same plane as the µUS images 
would provide a means of eliminating anomalous signals due to non-inflammatory 
sources such as debris.  However, low grade inflammation did not result in overt optical 
signs.  Therefore, a means of detecting accumulation of inflammatory cells would also be 
necessary. As leukocytes can be made to fluoresce through artificial or endogenous 
means, it offers a possible means of complimentary inflammatory imaging.  Post-mortem 
tissue can be labelled with fluorescent antibodies or made to fluoresce via endogenous 
molecules [246], [247].  By employing fluorescent imaging, it may be possible to detect 
monocyte aggregation at lower inflammatory grades.  Simultaneous µUS and optical 
fluorescent imaging would enable direct comparison between the two modalities and 
improve interpretation of anomalous US signals as illustrated in figure 7.4.    
 
 
Figure 7.4.  Conceptual image of a combined microultrasound (µUS) and optical fluorescent modality 
scanner.  Fluorescent imaging could provide an optical means to detect inflammatory cell accumulation.  
Post-mortem monocyte fluorescence could be achieved by either labelling with fluorescent tagged 
antibodies or inducing endogenous molecules to fluoresce.  Fluorescing leukocytes would permit optical 
visualisation of inflammation in conjunction with µUS scanning.  This would assist with categorising 
anomalous µUS signals as being created accumulated inflammatory cells.  Image adapted from Cox et 
al [245].      
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7.3. Related µUS Future Work    
As introduced in Chapter 2, the GI tract comprises a relatively massive area in which to 
examine at high resolution levels.  The surface area of the human GI tract is measured in 
square meters while µUS wavelengths are sub-mm in scale.  As it stands, standard optical 
CE interpretation times are considered lengthy and automated detection of pathology is 
absolutely needed [248].  The addition of a second imaging modality, namely µUS, would 
substantially increase the number of images requiring review.  An automated means of 
diagnosis is, therefore, essential to manage both data volume and interpretation times.  
Preliminary work focused on image processing and data analysis has been done [249] 
exploring machine learning to develop computer assisted diagnosis (CADx).  Early 
results have yet to be validated but have shown potential promise in distinguishing healthy 
tissue from inflamed [250].  
 
7.4. Summary and Conclusion 
The principal motivation driving this research was to improve the diagnosis and 
management of IBD and GI disorders in general.  The route taken involved the design 
and development of USCE.  Such a device could transit the entire GI tract and provide 
high resolution transmural µUS images to gain subsurface information on pathology.  
This, in turn, would enhance the ability to accurately monitor disease activity and improve 
treatment capabilities.  Clinicians could be provided a means to achieve complete 
histological remission without the need for tissue biopsy.  
My research into USCE used three species to test different aspect of USCE design and 
function.  Human tissue results indicated that a centre frequency of ≈35 MHz could 
provide satisfactory high resolution transmural images.  In vivo pig experiments 
successfully demonstrated USCE could generate cross-sectional bowel images.  
Inflammation experiments using mice showed that frequencies appropriate for human 
bowel dimensions could detect high grade inflammation in mice.  
USCE has the potential to positively impact the diagnosis and management of IBD and 
other GI disorders [251].  My work has successfully demonstrated the feasibility and 
potential of USCE.  The results of this endeavour have provided the foundation and 
impetus for continued research in this much needed area.    
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Appendix A 
Table A1.  Technical differences between μUS step and continuous sweep scanning systems.  Table 
adapted from T. Anbarasan, C.E.M. Démoré, H. Lay, M.R.S. Sunqrot, R. Poltarjonoks, S. Cochran, B.F. 
Cox., “High Resolution Microultrasound (μUS) Investigation of the Gastrointestinal (GI) Tract,” 2017, 
pp. 541–561 
 
Figure. 1A. Scanning automation algorithm for (A) μUS step scanner (B) μUS continuous sweep 
scanner. Figure adapted from T. Anbarasan, C.E.M. Démoré, H. Lay, M.R.S. Sunqrot, R. Poltarjonoks, 
S. Cochran, B.F. Cox., “High Resolution Microultrasound (μUS) Investigation of the Gastrointestinal 
(GI) Tract,” 2017, pp. 541–561. 
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Table 1B. Haematoxylin and Eosin (H&E) staining from Calum Thomson 
 
